document incorporate reference document proxy statement annual meeting shareholder hold file iii security exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common equity relate stockholder matter issuer purchase equity security item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum afinancial statement note consolidated financial statement report independent register public accounting firm item change disagreement accountant account financial disclosure item control procedure management report item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule item summary signature table content item business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operate segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer company previously healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company divest remain business segment quarter company previously alliance segment primarily include activity company relationship astrazeneca relate sale nexium prilosec conclude product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner plan spinoff women health biosimilar establish brand new company february merck announce intention spinoff spinoff product women health biosimilar establish brand business new independent publicly trade company name organon organon distribution organon publicly trade stock company shareholder distribution expect qualify taxfree company shareholder federal income tax purpose establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product include zetia ezetimibe vytorin ezetimibesimvastatin rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan organon development capability initially focus latestage development lifecycle management expect time develop research capability select therapeutic area spinoff expect complete late second quarter subject market certain condition risk factor risk relate propose spinoff organon table content product sale total company sale include sale company pharmaceutical product sale animal health product follow million total sale pharmaceutical keytruda januviajanumet gardasilgardasil proquadmmr iivarivax bridion pneumovax isentressisentress simponi rotateq alliance revenue lynparza implanonnexplanon zetiavytorin alliance revenue lenvima animal health livestock companion animal revenue alliance revenue represent merck share profit product sale net cost sale commercialization cost revenue primarily comprise thirdparty manufacture sale miscellaneous corporate revenue include revenue hedging activity pharmaceutical pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder human health vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office certain product company franchise follow oncology keytruda pembrolizumab company antipd program death receptor therapy monotherapy treatment certain patient cervical cancer classical hodgkin lymphoma chl cutaneous squamous cell carcinoma cscc esophageal cancer gastric gastroesophageal junction adenocarcinoma head neck squamous cell carcinoma hnscc hepatocellular carcinoma hcc nonsmallcell lung cancer nsclc smallcell lung cancer sclc melanoma merkel cell carcinoma microsatellite instabilityhigh msih mismatch repair deficient dmmr cancer include msihdmmr colorectal cancer primary mediastinal large bcell lymphoma pmbcl tumor mutational burdenhigh tmbh cancer urothelial carcinoma include nonmuscle invasive bladder cancer keytruda approve treatment certain patient combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy hnscc combination chemotherapy triplenegative breast cancer combination axitinib renal cell carcinoma combination lenvatinib endometrial carcinoma emend aprepitant prevention certain chemotherapyinduce nausea vomit addition company recognize alliance revenue relate sale lynparza olaparib oral poly adpribose polymerase parp inhibitor certain type advance ovarian breast pancreatic prostate cancer lenvima lenvatinib certain type thyroid cancer hepatocellular carcinoma combination everolimus certain patient renal cell carcinoma combination keytruda certain patient endometrial carcinoma vaccine gardasil human papillomavirus quadrivalent type vaccine recombinantgardasil human papillomavirus valent vaccine recombinant vaccine help prevent certain disease table content cause certain type human papillomavirus hpv proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump rubella varicella mmr measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child vaqta hepatitis vaccine inactivated indicate prevention disease cause hepatitis virus person month age old hospital acute care bridion sugammadex injection medication reversal type neuromuscular block agent surgery noxafil posaconazole antifungal agent prevention certain invasive fungal infection prevymis letermovir prophylaxis cytomegalovirus cmv reactivation disease adult cmvseropositive recipient allogeneic hematopoietic stem cell transplant primaxin imipenem cilastatin injection antibiotic treatment certain bacterial infection cancida caspofungin acetate injection antifungal agent treatment certain fungal infection invanz ertapenem injection antibiotic treatment certain bacterial infection cubicin daptomycin injection antibiotic treatment certain bacterial infection zerbaxa ceftolozane tazobactam injection combination antibacterial betalactamase inhibitor treatment certain bacterial infection immunology simponi golimumab oncemonthly subcutaneous treatment certain inflammatory disease remicade infliximab treatment inflammatory disease company market europe russia turkey neuroscience belsomra suvorexant orexin receptor antagonist indicate treatment insomnia characterize difficulty sleep onset andor sleep maintenance virology isentressisentress raltegravir hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection zepati elbasvir grazoprevir treatment adult patient chronic hepatitis virus hcv genotype infection ribavirin certain patient population cardiovascular zetia ezetimibe market ezetrol country outside united states vytorin ezetimibesimvastatin market inegy outside united states atozet ezetimibe atorvastatin market outside united states rosuzet ezetimibe rosuvastatin market outside united states cholesterol modifying medicine adempas riociguat cardiovascular drug treatment pulmonary arterial hypertension diabete januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabete womens health implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshape subdermal contraceptive implant nuvare etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product animal health animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine health management solution service extensive suite digitally connect identification traceability monitoring product principal product segment include livestock product nuflor florfenicol antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine flunixin meglumine bovine swine antiinflammatory estrumate cloprostenol sodium treatment fertility disorder cattle matrix altrenogest fertility management swine resflor florfenicol flunixin meglumine combination broadspectrum antibiotic nonsteroidal antiinflammatory table content drug bovine respiratory disease zuprevo tildipirosin bovine respiratory disease zilmax zilpaterol hydrochloride revalor trenbolone acetate estradiol improve production efficiency beef cattle safeguard fenbendazole dewormer cattle mpac mycoplasma hyopneumoniae bacterin swine pneumonia vaccine porcilis lawsonia intracellularis baterin circumvent porcine circovirus vaccine type kill baculovirus vector vaccine line infectious disease swine nobilisinnovax live marek disease vector vaccine line poultry paracox coccivac coccidiosis vaccine exzolt systemic treatment poultry red mite infestation slice emamectin benzoate parasiticide sea lice salmon aquavac avirulent live culturenorvax vaccine bacterial viral disease fish compact vaccine salmon aquaflor florfenicol antibiotic farmraised fish allflex livestock intelligence solution animal identification monitor traceability companion animal product bravecto line oral topical parasitic control product include original bravecto fluralaner product dog cat week bravecto fluralaner onemonth monthly product dog bravecto plus fluralanermoxidectin twomonth product cat sentinel line oral parasitic product dog include sentinel spectrum milbemycin oxime lufenuron praziquantel sentinel flavor tab milbemycin oxime lufenuron optimmune cyclosporine ophthalmic ointment nobivac vaccine line flexible dog cat vaccination otomax gentamicin sulfate usp betamethasone valerate usp clotrimazole usp ointmentmometamax gentamicin sulfate usp mometasone furoate monohydrate clotrimazole usp otic suspensionposatex orbifloxacin mometasone furoate monohydrate posaconazole suspension ear ointments acute chronic otitis caninsulinvetsulin porcine insulin zinc suspension diabetes mellitus treatment dog cat panacur fenbendazolesafeguard fenbendazole broad spectrum anthelmintic dewormer use animal regumate altrenogest fertility management horse prestige vaccine line horse scalibor deltamethrinexspot protect bite flea tick mosquitoe sandfly sure petcare product companion animal identification wellbee include microchip pet recovery system home discussion sale company product item management discussion analysis financial condition result operation product approval set forth summary significant product approval receive company product date approval food drug administration fda approve dificid oral suspension dificid tablet dificid january treatment clostridioide clostridium difficileassociate diarrhea child age month old china national medical products administration nmpa grant expand approval gardasil gardasil november use girl woman year age japans ministry health labour welfare mhlw approve additional indication dosage administration gardasil market silgard prevention anal cancer squamous cell cancer precursor lesion anal intraepithelial neoplasia grade cause hpv type december individual year old genital wart condyloma acuminate man year old japan pharmaceutical medical devices agency pmda approve gardasil use girl gardasil woman year old prevention cervical cancer certain cervical vaginal vulvar july precancer genital wart cause hpv type cover vaccine fda grant accelerated approval expand indication gardasil prevention june oropharyngeal head neck cancer cause hpv type table content nmpa approve keytruda monotherapy firstline treatment patient metastatic unresectable recurrent hnscc tumor express pdl combine positive score cp december determine fully validate test fda grant accelerated approval keytruda combination chemotherapy patient november locally recurrent unresectable metastatic triplenegative breast cancer tumor express pdl cp fda approve expand label keytruda monotherapy treatment adult patient october relapse refractory chl pmda approve keytruda use additional recommend dosage week administer intravenous infusion minute adult indication include august keytruda monotherapy combination therapy pmda approve keytruda treatment patient tumor pdlpositive radically unresectable advanced recurrent esophageal squamous cell carcinoma escc august progress chemotherapy fda approve keytruda monotherapy firstline treatment patient unresectable june metastatic msih dmmr colorectal cancer keytruda fda approve keytruda monotherapy treatment patient recurrent metastatic cscc june curable surgery radiation nmpa approve keytruda monotherapy treatment patient locally advanced metastatic escc tumor express pdl cp determine fully validate test june follow failure prior line systemic therapy fda grant accelerated approval keytruda monotherapy treatment adult pediatric patient unresectable metastatic tmbh mutationsmegabase mutmb solid tumor determine fdaapprove test progress follow prior treatment june satisfactory alternative treatment option fda grant accelerated approval keytruda use additional recommend dose april week approve adult indication fda approve keytruda patient bacillus calmetteguerin bcgunresponsive highrisk non muscle invasive bladder cancer carcinoma situ papillary tumor ineligible january elect undergo cystectomy fda approve kinase inhibitor koselugo treatment pediatric patient year age koselugo april old neurofibromatosis type symptomatic inoperable plexiform neurofibroma lenvima november nmpa approve lenvima monotherapy treatment differentiate thyroid cancer table content pmda approve lynparza treatment patient brca genemutate brcam castration december resistant prostate cancer distant metastasis pmda approve lynparza maintenance treatment platinumbase chemotherapy patient december brcam curatively unresectable pancreas cancer pmda approve lynparza maintenance treatment firstline chemotherapy contain bevacizumab genetical recombination patient homologous recombination repair deficient december hrd ovarian cancer european commission approve lynparza maintenance treatment adult patient advance figo stage iii highgrade epithelial ovarian fallopian tube primary peritoneal cancer response complete partial follow completion firstline platinum base chemotherapy combination bevacizumab cancer associate hrd november positive status define breast cancer susceptibility gene brca mutation andor genomic instability approve lynparza monotherapy treatment adult patient metastatic castration lynparza resistant prostate cancer mcrpc brca mutations germline andor somatic november progress follow prior therapy include new hormonal agent approve lynparza monotherapy maintenance treatment adult patient germline brca mutation metastatic adenocarcinoma pancrea progress minimum week platinum treatment firstline chemotherapy regiman july fda approve lynparza treatment adult patient deleterious suspect deleterious germline somatic homologous recombination repair hrr genemutate mcrpc determine fdaapprove test progress follow prior treatment enzalutamide abiraterone fda approve lynparza combination bevacizumab firstline maintenance treatment adult patient advance epithelial ovarian fallopian tube primary peritoneal cancer complete partial response firstline platinumbase chemotherapy cancer associate hrd positive status define deleterious suspect deleterious brca mutation andor genomic instability determine fdaapprove test fda approve recarbrio treatment patient year age old hospitalacquire recarbrio june bacterial pneumonia ventilatorassociate bacterial pneumonia habpvabp steglatro july nmpa approve steglatro tablet treatment type diabete dificid canada trademark cubist pharmaceutical llc indirect whollyowne subsidiary merck sharp dohme corp july merck astrazeneca enter global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza koselugo commercialized promote worldwide japan collaboration pfizer inc table content competition health care environment competition market company conduct business pharmaceutical industry general highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug manufacturer animal health care company companys operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent right increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result payment royalty recognition impairment charge respect intangible asset associate certain product pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively long stand emphasis research development company wellpositione compete search technological innovation company active acquire marketing product external alliance license arrangement collaboration refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product competitor product effective promotional effort frequent introduction generic product competitor health care environment government regulation global effort health care cost containment continue exert pressure product pricing market access united states united states federal state government year pursue method reduce cost drug vaccine pay example federal state law require company pay specify rebate medicine reimburse medicaid provide discount medicine purchase certain state federal entity department defense veteran affairs public health service entity hospital serve disproportionate share low income uninsured patient health care program united states enact major health care reform legislation aca insurance market reform advanced state federal insurance exchange launch respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay cost medicine include biosimilar product medicare beneficiary medicare coverage gap socalle donut hole increase beginning result balanced budget act merck record approximately million million million reduction revenue respectively relate donut hole provision pharmaceutical manufacturer require pay annual nontax deductible health care reform fee total annual industry fee set billion fee assess company proportion share prior year brand pharmaceutical sale certain government program medicare medicaid company record approximately million million million cost sell general administrative table content expense respectively annual health care reform fee february center medicare medicaid services cms issue medicaid rebate final rule implement provision aca effective april rule provide comprehensive guidance calculation average manufacturer price good price metric utilize determine rebate drug manufacturer require pay state medicaid program recently cms previously decline define constitute product line extension statutory definition cms issue new rule december significantly expand definition term line extension january include broad range product include product reflect new strength dosage form release mechanism route administration expand definition increase number drug subject high medicaid rebate effective january final rule change way manufacturer calculate good price relation certain patient support program include coupon result increase company medicaid rebate impact provision final rule adversely impact company business cash flow result operation financial condition prospect patient protection affordable care act significant uncertainty future aca particular health care law general united states december texas federal district court strike aca ground individual health insurance mandate unconstitutional united states supreme court hear argument case november company participate health care debate monitoring propose change affect business company unable predict likelihood change aca depend nature change aca action material adverse effect company business cash flow result operation financial condition prospect legislative change addition legislative change propose adopt united states aca enact number state pass pharmaceutical price cost transparency law law typically require manufacturer report certain product price information financial datum state law require manufacturer provide advance notification price increase company expect state continue focus pharmaceutical price transparency focus continue exert pressure product pricing drug pricing company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin include united states practice manage care organization federal state exchange institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act aca november department health human service office inspector general oig issue final rule effective january eliminate antikickback statute safe harbor rebate pay medicare plan pharmacy benefit manager pbms behalf plan company anticipate effect change way currently contract new framework significantly alter way business plan sponsor pbms behalf plan rulemake establish effective january new safe harbor point sale discount pharmacy counter new safe harbor certain service arrangement pharmaceutical manufacturer pbms cms recently issue interim final rule mfn rule alter physicians reimburse medicare program physician administer drug pursuant mfn rule intend effective january use current average sale price aspbase payment framework certain physicianadministere drug mfn rule institute new pricing system certain prescription drug biologic product cover medicare medicare reimburse favor nation price mean low price adjust volume difference gross domestic product reimburse product include keytruda sell member country organisation economic cooperation development oecd organization include table content trade group merck member file suit challenge regulation lawsuit remain pende preliminary injunction enter case time company predict certainty mfn rule effect implementation mfn rule material adverse effect company business cash flow result operation financial condition prospect fda recently issue rulemaking allow commercial importation certain prescription drug canada fdaauthorize time limited program sponsor states native american tribe recognize rule certain future circumstance pharmacist wholesaler fda recently release final guidance industry detail procedure drug manufacturer import fdaapprove prescription drug biological combination product manufacture abroad authorize intend sale foreign country trade organization merck member bring suit remain pende federal district court challenge commercial importation rule propose change material adverse effect company business cash flow result operation financial condition prospect change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure example health care reform contribute increase number patient medicaid program sale pharmaceutical product subject substantial rebate pharmaceutical industry consider potential source saving legislative administrative proposal debate enact type revenue generating cost saving proposal include additional direct price control active consideration drugprice related legislation congress remain uncertain proposal include future federal legislative proposal directly indirectly affect company private sector consolidation integration health care provider major factor competitive marketplace pharmaceutical product health plan pbms consolidate few large entity enhance purchasing strength importance private thirdparty insurer government employ formulary control cost negotiate discount price exchange formulary inclusion failure obtain timely adequate pricing formulary placement merck product obtain placement unfavorable pricing adversely affect revenue addition formulary tier copay differential private health insurance company selfinsure employer raise copayment require beneficiary particularly brand pharmaceutical biotechnology product private health insurance company increasingly impose utilization management tool clinical protocol require prior authorization brand product generic product available require patient fail generic product permit access brand medicine management tool treatment area payor take position multiple brand product therapeutically comparable payor market concentrate drug available generic form pharmaceutical company face great pricing pressure private thirdparty payor order provide information company pricing practice company annually post website pricing transparency report united states report provide company average annual list price net price increase average discount company portfolio date company gross sale reduce result rebate discount return european union effort health care cost containment remain intense european union company face competitive pricing pressure result generic biosimilar drug addition majority country attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug reference pricing compare product price market external reference pricing compare product price product national class internal reference pricing authority use price datum set new local price brandname drug include company drug guideline examine reference pricing usually set local market change table content pursuant local regulation member states establish freeprice system regulate pricing drug profit control plan seek negotiate set price base costeffectiveness product assessment offer therapeutic benefit product relevant class downward pressure health care cost general particularly prescription drug intense result increasingly high barrier erect entry new product member states crossborder import lowprice market exert competitive pressure reduce pricing member state additionally member states power restrict range pharmaceutical product national health insurance system provide reimbursement pricing reimbursement plan vary widely member state member state member state provide drug product marketed reimbursement price agree member states require completion additional study compare cost effectiveness particular product candidate available therapy socalle health technology assessment hta order obtain reimbursement pricing approval hta pharmaceutical product increasingly common price reimbursement procedure member states hta process govern national law country involve assessment costeffectiveness public health impact therapeutic impact andor economic social impact use give pharmaceutical product national health care system individual country conduct ultimately hta measure add value new health technology compare exist one outcome hta specific pharmaceutical product influence pricing reimbursement status grant pharmaceutical product regulatory authority individual member states negative hta company product mean product reimbursable force company reduce reimbursement price offer discount rebate negative hta leading recognize hta body undermine company ability obtain reimbursement relevant product outside jurisdiction example member states develop hta mechanism rely extent hta perform country develop hta framework inform pricing reimbursement decision hta procedure require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement obtain reimbursement pricing approval member states company require conduct study compare cost effectiveness company product candidate therapy consider local standard care assurance member state allow favorable pricing reimbursement market access condition company product feasible conduct additional costeffectiveness study require brexit united kingdom hold referendum voter approve exit commonly refer brexit result referendum subsequent negotiation leave january transitional period apply january december period operate member state continue participate customs union allow freedom movement people good announce december agree trade cooperation agreement tca tca set new arrangement trade good include medicine vaccine allow good continue flow december council adopt decision sign tca tca provisionally apply january sign tca december order tca ratified formally come effect council unanimously approve tca european parliament consent company believe occur result tca company believe operation materially adversely affect brexit table content japan japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine furthermore government order repricing specific product determine use product exceed certain threshold define applicable repricing rule governmentmandate price reduction occur april expect impact company product china company business china grow rapidly past year importance china company overall pharmaceutical vaccine business increase accordingly continue growth company business china dependent ongoing development favorable environment innovative pharmaceutical product vaccine sustain access company current inline product absence trade impediment adverse pricing control recent year chinese government introduce implement number structural reform accelerate shift innovative product reduce cost multiple new policy introduce government improve access new innovation reduce complexity regulatory filing accelerate review approval process lead significant increase number new product approve year additionally chinese government update national reimbursement drug list nrdl time year mechanism drug add list evolve inclusion require price negotiation impact outlook market select brand drug add nrdl doubledigit price reduction pricing pressure exist china health care reform increase pressure acceleration generic substitution volume base procurement vbp government implement vbp program tendering process mature product generic substitute generic quality consistency evaluation approval mature product enter round vbp average price reduction company expect vbp semiannual process significant impact mature product move forward emerge market company focus emerge market addition china continue government emerge market focus constrain health care cost enact price control measure impact intellectual property include exceptional case threat compulsory license aim pressure price innovative pharmaceutical result constrain market access innovative medicine company anticipate pricing pressure market access challenge continue future vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability change trade sanction embargo significant currency fluctuation control financial crisis limit change availability funding health care credit worthiness health care partner hospital covid development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization table content business practice well meet customer need believe wellpositione respond evolve health care environment market force regulation pharmaceutical industry subject regulation regional country state local agency world focus standard process determine drug safety effectiveness condition sale reimbursement particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states time fda commit expedite development review product bear breakthrough therapy designation accelerate regulatory review process medicine designation fda undertake effort bring generic competition market efficiently timely manner adopt directive legislation concern classification approval marketing labeling advertising manufacture wholesale distribution integrity supply chain pharmacovigilance safety monitor medicinal product human use provide mandatory standard supplemented implement additional regulation member states particular regulator approve product subject number postauthorization condition example typical postauthorization commitment include additional pharmacovigilance conduct clinical trial establishment patient registry physician patient education control distribution prescribing arrangement non compliance postauthorization condition pharmacovigilance obligation lead regulatory action include variation suspension withdrawal marketing authorization enforcement regulatory action include imposition financial penalty company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment research development discussion regulatory approval process access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access medicine vaccine quality health care world company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care addition innovative social investment include philanthropic program impact investing merck help strengthen health system build capacity particularly underresourced community merck patient assistance program provide medicine adult vaccine free people united states prescription drug health insurance coverage company assistance afford merck medicine vaccines merck fund merck mother longterm effort global health partner end preventable death complication pregnancy childbirth merck provide fund merck foundation independent grantmaking organization partner variety organization dedicate improve global health privacy datum protection company subject significant number privacy datum protection law regulation globally place restriction company ability transfer access use personal datum business legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include general data protection regulation gdpr go effect impose penalty global revenue table content gdpr related implement law individual member states govern collection use personal health datum personal datum gdpr increase responsibility liability relation personal datum company process impose number strict obligation restriction ability process include collection analysis transfer personal datum include health datum clinical trial adverse event report gdpr include requirement relate consent individual personal data relate information provide individual prior process personal datum personal health datum notification datum processing obligation national datum protection authority security confidentiality personal datum gdpr prohibits transfer personal data country outside consider provide adequate level datum protection include united state datum controller meet specific requirement follow schrems decision court justice european union july considerable uncertainty permissibility international data transfer gdpr light implication decision company face difficulty transfer personal datum country failure comply requirement gdpr related national datum protection law member states result significant monetary fine administrative penalty civil liability claim individual personal datum process datum protection authority different member state implement certain variation enforce gdpr national datum protection law differently introduce additional national regulation guideline add complexity process personal datum guidance develop level national level individual member state concern implementation compliance practice update revise grow trend require public disclosure clinical trial datum add complexity obligation relate processing health datum clinical trial fail comply obligation lead government enforcement action significant penalty company harm reputation adversely impact business operating result uncertainty interplay different regulatory framework add complexity company face regard datum protection regulation additional law regulation enact united states california consumer privacy act europe asia latin america increase enforcement litigation activity united states develop market increase regulatory cooperation privacy authority globally company adopt comprehensive global privacy program manage evolve risk facilitate transfer personal information international border distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pbms institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer patent trademark license patent protection consider aggregate material importance company marketing product united states major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage food drug administration modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant current patent law table content provide additional patent term period patent product regulatory review fda provide additional month pediatric market exclusivity attach product supplementary protection certificate spc japan provide additional term pediatric study attach market exclusivity unrelated patent term patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection united states japan china include potential patent term extension pte spc indicate follow market product product year expiration year expiration year expiration japan year expiration china januvia janumet janumet isentress simponi lenvima pende pte patent spc adempas bridion pende pte expire nexplanon device device bravecto pende pte patent spc gardasil expire gardasil patent spc keytruda patent spc lynparza pende pte patent spcs zerbaxa patent spc pende pte sivextro patent spcs belsomra prevymis pende pte patent spc segluromet pende pte patent spc steglatro pende pte patent spc steglujan pende pte patent spc verquvo pende pte delstrigo pende pte patent spc pifeltro pende pte patent spc recarbrio pende pte note compound patent note certain product list subject patent litigation item financial statement supplementary datum note contingency environmental liability currently market approval table content date represent expiration date follow country france germany italy spain united kingdom major market spc application file grant major markets patent expiry date spc expiry date list pte system japan allow patent extend provide later approval direct different indication previous approval result multiple pte approval give patent expiration date eligible month pediatric exclusivity company marketing right japan china expiration distribution agreement janssen pharmaceuticals inc global strategic oncology collaboration eisai commercialize worldwide collaboration bayer global strategic oncology collaboration astrazeneca commercialize promote worldwide japan collaboration pfizer inc company marketing right japan company marketing right japan china company follow key patent protection drug candidate review phase development currently anticipate phase drug candidate year expiration gefapixant pneumoconjugate vaccine vaccine composition cdfc mka islatravirdoravirine belzutifan note patent chart compound patent patent subject future patent term restoration year month pediatric market exclusivity available addition depend circumstance surround final regulatory approval compound list patent patent application pende relevance product finally approve relevance application depend claim ultimately grant nature final regulatory approval product regulatory exclusivity tie protection clinical data complementary patent protection case provide effective long last marketing exclusivity compound patent estate united states data protection generally run year marketing approval new chemical entity extend seven year orphan drug indication year marketing approval biological product expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation united states certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability table content worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold research development company business characterize introduction new product new use exist product strong research development program december approximately people employ company research activity company prioritize research development effort focus candidate believe represent breakthrough science difference patient payer company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologic capability company commit ensure externally source program remain important component pipeline strategy focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company clinical pipeline include candidate multiple disease area include cancer cardiovascular disease metabolic disease infectious disease neuroscience respiratory disease vaccine development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed united states record datum preclinical clinical experience include new drug application nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness situation clinical program incorporate adaptive design methodology use accumulate datum decide modify aspect ongoing clinical study continue undermine validity integrity trial type adaptive clinical trial adaptive phase trial design twostage trial design consist phase proofofconcept stage phase doseoptimization finding stage datum phase trial satisfactory company commence largescale phase trial confirm compound efficacy safety type adaptive clinical trial adaptive phase trial design study include interim analysis adaptation change trial feature common phase study multiple dose group design similar phase trial adaptive phase trial design reduce timeline eliminate activity require start separate study completion phase trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing table content assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase study doserange study finally phase trial provide necessary datum effectiveness safety successful company submit regulatory filing appropriate regulatory agency united states fda review process begin complete nda bla submit receive accept review agency day receipt fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review pursuant prescription drug user fee act pdufa fda review period target nda original bla month priority review month standard review time application deem sufficiently complete review timeline determine fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue complete response letter crl state application approve present form describe deficiency fda identify company wish pursue application receive crl resubmit application information address question issue identify fda order support approval resubmission subject review period target vary depend underlie submission type content resubmission fda program designation fast track breakthrough therapy accelerate approval priority review facilitate expedite development review new drug address unmet medical need treatment lifethreatening condition fast track designation provide pharmaceutical manufacturer opportunitie frequent interaction fda reviewer product development ability manufacturer roll submission ndabla rolling submission allow complete portion application submit review fda ongoing basis breakthrough therapy designation provide manufacturer feature fast track designation intensive guidance implement efficient development program product commitment fda involve senior manager experience staff review accelerate approval designation allow fda approve product base effect surrogate intermediate endpoint reasonably likely predict product clinical benefit generally require manufacturer conduct require postapproval confirmatory trial verify clinical benefit priority review designation mean fda goal action ndabla month compare month standard review special designation grant give application product designate breakthrough therapy eligible priority review covid public health crisis united states secretary health human service exercise statutory authority determine public health emergency exist declare circumstance justify emergency use drug biological product authorize fda effect declaration enable fda issue emergency use authorization euas permit distribution use specific medical product absent ndabla submission approval include product treat prevent disease condition cause sarscov virus subject term euas fda certain finding grant eua include reasonable believe base totality evidence drug biologic effective know potential benefit term eua outweigh know potential risk additionally fda find adequate approve available alternative emergency use primary method company use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product table content particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member states outside united states company submit marketing application national regulatory authority example ministry health labour welfare japan national medical products administration china health canada agncia nacional vigilncia sanatria brazil korea food drug administration south korea therapeutic goods administration australia country separate independent review process timeline market approval time long regulatory authority require approval major market united states issuance certificate pharmaceutical product market initiate local review process research development update company currently candidate regulatory review united states internationally latestage clinical development mka combination relebactum betalactamase inhibitor imipenemcilastatin carbapenem antibiotic review japan treatment bacterial infection mka approve fda market united states recarbrio vericiguat orally administer soluble guanylate cyclase sgc stimulator review japan reduce risk cardiovascular death heart failure hospitalization follow worsen heart failure event patient symptomatic chronic heart failure reduce ejection fraction combination heart failure therapie application base result phase victoria trial vericiguat approve fda january market united states verquvo vericiguat jointly develop bayer bayer commercialize vericiguat territory outside united states approve selumetinib review treatment pediatric patient year age old neurofibromatosis type symptomatic inoperable plexiform neurofibroma base positive result national cancer institute cancer therapy evaluation program sponsor phase sprint stratum trial selumetinib approve fda april market united states koselugo selumetinib jointly develop commercialize astrazeneca globally investigational valent pneumococcal conjugate vaccine priority review fda prevention invasive pneumococcal disease adult year age old fda set pdufa date july ema review application licensure adult additionally company ongoing phase trial evaluate pediatric patient previously receive breakthrough therapy designation fda prevention invasive pneumococcal disease pediatric patient week year age adult year age old company involve litigation challenge validity pfizer inc patent relate pneumococcal vaccine technology united states foreign jurisdiction keytruda antipd therapy approve treatment cancer clinical development expand indication approval result broad clinical development program currently consist clinical trial include trial combine keytruda cancer treatment study encompass cancer type include biliary tract cervical colorectal cutaneous squamous cell endometrial esophageal estrogen receptor positive breast cancer gastric glioblastoma head neck hepatocellular hodgkin lymphoma nonhodgkin lymphoma nonsmallcell lung smallcell lung melanoma mesothelioma ovarian prostate renal triplenegative breast urothelial currently phase clinical development trial plan cancer table content keytruda combination chemotherapy review treatment locally recurrent unresectable metastatic triple negative breast cancer tnbc adult tumor express pdl cp receive prior chemotherapy metastatic disease base result keynote trial keytruda approve indication accelerate approval base progressionfree survival pfs fda november keytruda combination chemotherapy review japan treatment patient locally recurrent unresectable metastatic tnbc base datum keynote trial july fda accept standard review supplemental bla keytruda treatment patient highrisk earlystage tnbc combination chemotherapy neoadjuvant preoperative treatment single agent adjuvant postoperative treatment surgery application base datum second interim analysis keynote trial february fdas oncologic drug advisory committee odac discuss company supplemental bla keytruda vote regulatory decision defer datum available phase keynote trial study meet dual primary endpoint pathological complete response continue evaluate eventfree survival odac provide fda independent expert advice recommendation market investigational medicine use treatment cancer fda bind committee guidance take advice consideration pdufa date application march interim analysis calendardriven datum expect quarter february merck announce committee medicinal product human use chmp ema adopt positive opinion recommend approval expand label keytruda monotherapy treatment adult pediatric patient age year old relapse refractory chl fail early line therapy recommendation base result pivotal phase keynote trial keytruda monotherapy demonstrate significant improvement pfs compare brentuximab vedotin commonly treatment recommendation base supportive datum update analysis keynote trial support approval keytruda treatment adult patient relapse refractory chl chmp recommendation review marketing authorization keytruda approve indication fda october keytruda review monotherapy firstline treatment adult patient metastatic msih dmmr colorectal cancer japan base result keynote trial keytruda approve indication fda june january january fda accept supplemental bla seeking use keytruda treatment patient locally advanced cscc curable surgery radiation base result keynote trial fda set pdufa date september december fda accepted grant priority review supplemental bla keytruda combination chemotherapy firstline treatment patient locally advance unresectable metastatic carcinoma esophagus gastroesophageal junction supplemental bla base datum pivotal phase keynote trial keytruda plus chemotherapy demonstrate significant improvement primary endpoint overall survival pfs versus chemotherapy patient regardless pdl expression status tumor histology datum present european society medical oncology esmo virtual congress fda set pdufa date april december chmp ema announce start procedure extend indication include combination chemotherapy firstline treatment locally advanced unresectable metastatic carcinoma esophagus negative gastroesophageal junction adenocarcinoma adult keytruda base result keynote keytruda review indication japan keytruda receive breakthrough therapy designation fda february combination keytruda padcev enfortumab vedotinejfv firstline set treatment patient unresectable locally advanced metastatic urothelial cancer eligible cisplatin contain chemotherapy fda breakthrough therapy designation intend expedite development review candidate plan use combination treat lifethreatening disease condition preliminary clinical evidence indicate drug demonstrate substantial improvement exist therapy clinically significant endpoint table content january merck announce firsttime datum phase keynote study evaluate keytruda combination ipilimumab yervoy compare keytruda monotherapy firstline treatment patient metastatic nsclc egfr alk genomic tumor aberration tumor express pdl tumor proportion score result study show addition ipilimumab keytruda improve pfs add toxicity compare keytruda monotherapy patient result present presidential symposium iaslc world conference lung cancer host international association study lung cancer january publish journal clinical oncology previously announce november study discontinue futility base recommendation independent datum monitor committee dmc determine benefitrisk profile keytruda combination ipilimumab support continue trial dmc advise patient study discontinue treatment ipilimumabplacebo february mercks announce phase keynote trial evaluate keytruda versus standard care treatment capecitabine gemcitabine docetaxel treatment recurrent metastatic nasopharyngeal cancer meet primary endpoint result present future medical meeting merck eisai present datum analyse phase trial evaluate keytruda plus lenvima american society clinical oncology asco annual meeting keytruda plus lenvima combination demonstrate clinically meaningful objective response rate orr keynotestudy trial patient unresectable hcc prior systemic therapy keynotestudy trial patient metastatic clear cell renal cell carcinoma ccrcc progress follow immune checkpoint inhibitor therapy july merck eisai announce fda issue crl merck eisais application seek accelerate approval line treatment patient unresectable hcc base trial show clinically meaningful efficacy singlearm set datum support breakthrough therapy designation grant fda july ahead pdufa action date merck eisais application combination therapy approve base randomize control trial demonstrate improvement versus standardofcare treatment consequently crl state merck eisais application provide evidence keytruda combination lenvima represent meaningful advantage available therapy treatment unresectable metastatic hcc prior systemic therapy advanced disease application keynotestudy long meet criterion accelerate approval company plan work fda appropriate step include conduct control clinical trial demonstrate substantial evidence effectiveness clinical benefit combination leap phase trial evaluate keytruda plus lenvima combination firstline treatment advance hcc currently underway fully enrol crl impact current approve indication keytruda lenvima february merck eisai announce presentation new investigational datum pivotal phase clear study keynote study genitourinary cancer symposium asco publish simultaneously new england journal medicine trial evaluate combination keytruda plus lenvima lenvima plus everolimus versus sunitinib firstline treatment patient advance rcc keytruda plus lenvima demonstrate statistically significant clinically meaningful improvement pfs orr versus sunitinib lenvima plus everolimus show significant improvement pfs orr versus sunitinib merck eisai discuss datum regulatory authority worldwide intent submit marketing authorization application base result december merck eisai announce pivotal phase keynotestudy trial evaluate investigational use keytruda plus lenvima meet dual primary endpoint pfs secondary efficacy endpoint orr patient advance endometrial cancer follow prior platinumbase regimen positive result observe mismatch repair proficient pmmr subgroup itt study population include patient endometrial carcinoma pmmr patient disease msihdmmr base analysis conduct independent dmc keytruda plus lenvima demonstrate statistically significant clinically meaningful improvement pfs orr versus chemotherapy merck eisai discuss datum regulatory authority worldwide intent table content submit marketing authorization application base result plan present result upcoming medical meeting keynotestudy confirmatory trial keynotestudy support accelerated approval fda keytruda plus lenvima combination treatment patient advance endometrial carcinoma msih dmmr disease progression follow prior systemic therapy candidate curative surgery radiation merck eisai continuing study keytruda plus lenvima combination leap lenvatinib pembrolizumab clinical program trial different tumor type endometrial carcinoma hcc melanoma nsclc rcc squamous cell carcinoma head neck urothelial cancer biliary tract cancer colorectal cancer gastric cancer glioblastoma ovarian cancer tnbc belzutifan investigational hypoxiainducible factor hif inhibitor evaluate treatment patient von hippel lindau vhl diseaseassociate rcc nonmetastatic rcc tumor centimeter size immediate surgery require july fda grant breakthrough therapy designation belzutifan grant orphan drug designation belzutifan vhl disease designation base datum phase trial evaluate belzutifan patient vhlassociate ccrcc present asco annual meeting additionally phase datum show antitumor response vhl disease patient ccrcc tumor present esmo virtual congress february merck eisai begin phase trial examine lenvima combination belzutifan previously treat patient metastatic rcc tukysa small molecule tyrosine kinase inhibitor treatment herpositive cancer september seagen grant merck exclusive license enter codevelopment agreement merck accelerate global reach tukysa merck seagen announce collaboration globally develop commercialize seagens ladiratuzumab vedotin investigational antibodydrug conjugate target liv currently phase clinical trial breast cancer solid tumor collaboration pursue broad joint development program evaluate ladiratuzumab vedotin monotherapy combination keytruda tnbc hormone receptorpositive breast cancer livexpresse solid tumor lynparza oral parp inhibitor currently approve certain type advance ovarian breast pancreatic prostate cancer develop multiple cancer type collaboration astrazeneca gefapixant investigational orally administer selective receptor antagonist treatment refractory unexplained chronic cough september merck announce result ongoing pivotal phase trial cough cough evaluate efficacy safety gefapixant study adult patient treat gefapixant twice daily demonstrate statistically significant reduction hour cough frequency versus placebo weeks cough weeks cough gefapixant twice daily treatment arm meet primary efficacy endpoint phase study result present virtual european respiratory society international congress merck plan share datum cough cough regulatory authority worldwide know cdfc investigational treatment patient hospitalize covid merck obtain acquisition oncoimmune september oncoimmune report topline finding interim efficacy analysis phase study evaluate interim analysis datum participant plan enrollment indicate select hospitalize patient covid treat single dose show high probability improvement clinical status compare placebo define protocol risk death respiratory failure reduce result phase study consistent topline result receive february submit publication future study phase trial treatment graft versus host disease molnupiravir know orally available antiviral candidate treatment covid develop collaboration ridgeback biotherapeutic currently evaluate table content phase clinical trial hospital outpatient setting primary completion date phase study june company anticipate interim efficacy datum quarter mka combination islatravir company investigational oral nucleoside reverse transcriptase translocation inhibitor nrtti doravirine pifeltro evaluate treatment hiv infection october merck announce week datum phase trial nct evaluate efficacy safety mka treatmentnave adult hiv infection week finding demonstrate combination islatravir doravirine maintain virologic suppression similar delstrigo doravirinelamivudinetenofovir disoproxil fumarate finding consistent week result additional week datum study low rate participant meet definition protocoldefine virologic failure islatravir plus doravirine delstrigo treatment arm participant arm meet criterion resistance testing datum present virtual international congress drug therapy hiv infection hiv glasgow november merck announce collaboration bill melinda gates foundation foundation foundation commit provide funding support pivotal phase study investigate oncemonthly oral preexposure prophylaxis prep option woman adolescent girl high risk acquire hiv infection subsaharan africa study impower evaluate efficacy safety oncemonthly islatravir anticipate begin early merck funding impower clinical trial united states merck plan conduct additional study hiv prevention islatravir oncemonthly oral prep study include impower global phase clinical trial evaluate islatravir oncemonthly oral agent prep site world key population impact epidemic include man sex man transgend woman january fda accept standard review supplemental nda steglatro ertugliflozin incorporate result phase vertis cardiovascular outcomes trial product label vertis trial evaluate steglatro oral sodiumglucose cotransporter sglt inhibitor versus placebo add background standard care treatment patient type diabete atherosclerotic disease study meet primary endpoint noninferiority major adverse event mace composite death nonfatal myocardial infarction nonfatal stroke compare placebo key secondary endpoint superiority steglatro versus placebo time occurrence composite death hospitalization heart failure time death time occurrence composite renal death dialysistransplant double serum creatinine baseline meet prespecifie hypothesis statistical testing reduction hospitalization heart failure observe steglatro supplemental application submit ema currently review january company announce discontinuation clinical development program covid vaccine candidate follow merck review finding phase clinical study vaccine study generally tolerate immune response inferior see follow natural infection report sarscovcovid vaccine chart reflect company research pipeline february candidate show phase include specific product date candidate enter phase development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation note candidate phase additional indication therapeutic area respect cancer additional claim line extension formulation inline product show table content phase phase phase entry date review antiviral covid cancer new molecular entitiesvaccine molnupiravir keytruda bacterial infection cancer biliary tract september mka relebactamimipenemcilastatin jpn cervical october heart failure hematological malignancy cutaneous squamous cell august vericiguat jpn quavonlimab endometrial august pediatric neurofibromatosis type melanoma gastric selumetinib nonsmallcell lung hepatocellular pneumococcal infection adult solid tumor mesothelioma ovarian december head neck prostate smallcell lung advanced solid tumor belzutifan keytruda renal cell february certain supplemental filing advance solid tumor tukysa cancer breast october keytruda hematological malignancies lynparza metastatic triplenegative breast cancer nonsmallcell lung colorectal august keynote jpn nonsmallcell lung june earlystage triplenegative breast cancer nonsmallcell lung smallcell lung december keynote lenvima refractory classical hodgkin lymphoma nonsmallcell lung bladder keynote ladiratuzumab vedotin endometrial june unresectable metastatic msih dmmr colorectal cancer advance solid tumor gastric december keynote jpn breast head neck february cutaneous squamous cell cancer tukysa melanoma march keynote advance solid tumor nonsmallcell lung march advance unresectable metastatic colorectal cough esophageal cancer keynote gastric gefapixant march jpn lynparza covid firstline metastatic gastric cancer advance solid tumor december keynote vibostolimab hiv infection lenvima melanoma mka doravirineislatravir february firstline metastatic hepatocellular carcinoma nonsmallcell lung keynote lenvima thymic carcinoma ncchremora jpn advance solid tumor biliary tract colorectal glioblastoma footnote breast develop collaboration cutaneous squamous cell develop combination keytruda head neck melanoma develop monotherapy combination keytruda solid tumor july fda issue crl mercks eisais application chikungunya virus merck eisai intend submit additional datum available fda cytomegalovirus hiv prevention islatravir nonalcoholic steatohepatitis nash overgrowth syndrome miransertib pneumococcal vaccine adult respiratory syncytial virus schizophrenia human capital december company approximately employee worldwide approximately employ united state include puerto rico approximately thirdparty contractor globally approximately company employee timeemployee woman individual ethnically diverse background comprise approximately workforce united states respectively woman comprise member board director additionally company executive team include individual structural level chief executive table content officer woman approximately company employee represent collective bargaining group company recognize employee critical meet need patient customer ability excel depend integrity skill diversity employee talent acquisition company use comprehensive approach ensure recruit retention leadership development goal systematically execute company hire talented leader achieve improved gender parity representation dimension diversity company provide training manager external recruiting organization strategy mitigate unconscious bias candidate selection hiring process addition company utilize comprehensive communication strategy marketing outreach social medium strategic alliance partnership reach broad pool talent critical business area company hire approximately employee globe channel include company external career site diversity partnership employee referral university external source global diversity inclusion diversity inclusion fundamental company success core future innovation company foster globally diverse inclusive workforce employee create environment belong engagement equity empowerment company proactive intentional diversity hire development program advance talent company create competitive advantage leverage diversity inclusion accelerate business performance include foster global supplier diversity integrate diversity inclusion company commercialization strategy leverage employee insight improve performance addition effort company employee business resource group provide opportunity employee active contribute company inclusive culture work talent acquisition development business customer insight social community outreach gender ethnicity performance datum woman workforce woman workforce woman board director woman executive role woman management role member underrepresented ethnic group board director member underrepresented ethnic group executive role member underrepresented ethnic group workforce member underrepresente ethnic group management role new hire female new hire member underrepresented ethnic group report executive define chief executive officer structural level management role define manager direct report executive define note compensation benefit company provide valuable total reward package reflect commitment attract retain motivate talent support employee family stage life company continuously monitor adjust compensation benefit program ensure competitive contemporary helpful engaging support strategic imperative diversity inclusion equity flexibility quality security affordability example company add personal health care concierge service assist employee participate company medical plan health care table content needs align business support cancer care strategy company improve cancer screening benefit add resource provide immediate access lead cancer center excellence employee globally company implement minimum standard week pay parental leave inclusively apply parents united states company benefit rank quartile fortune company aon hewitt benefit index company include work mother good company rank consecutive year name work mother good company dad employee wellbee company commit help employee family improve health wellbeing company culture wellbee refer live include program support preventive health emotional financial wellbee physical fitness nutrition design inspire employee pursue enjoy share healthy lifestyle live launch united states today available country company employee addition company large site offer onsite health clinic provide array service help employee stay include vaccination cancer biometric screening travel medicine advice diagnosis treatment nonoccupational illness injurie health counseling referral company overall employee wellbee program recognize excellence health wellbeing receive high level award business group health american heart association covid response company recognize unique responsibility help response covid pandemic committed support protect employee family ensure supply medicine vaccine reach patient contribute scientific expertise development antiviral approach support health care provider community serve company continue provide employee easy regular access information include detail company tracking process guidance hygiene measure travel good practice work home example pandemic support resource program available company employee include pay continuation worker sick expose volunteer policy adjustment enable employee medical background volunteer sarscovrelate activity resource prioritize physical mental wellness adjustment medical plan cover covidrelated diagnosis testing treatment backup childcare engage employee company strive foster employee engagement promote safe positive diverse inclusive work environment provide numerous opportunity twoway communication employee company key program initiative include promote global employee engagement survey ongoe pulse check organization interim feedback specific topic foster professional networking collaboration identify provide opportunity volunteer establish positive cooperative business relation designate employee representative talent management development company pursue goal world premier researchbase biopharmaceutical company needs continuously develop diverse talented people company current talent management system support companywide performance management development talent review succession plan annual performance review help professional development company employee ensure company workforce align company objective company seeks continuously build skill capability workforce accelerate talent improve performance mitigate risk relevant continuous learning experience include limited building leadership management skill provide technical functional training employee environmental matter company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure table content remediation environmental liability million estimate million aggregate year amount consider potential recovery party company take active role identify accrue cost management opinion liability environmental matter probable reasonably estimable accrue total million december possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure material adverse effect company financial condition result operation liquidity capital resource year merck believe climate change present risk business potential impact climate change business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy usage water use greenhouse gas emission company believe risk material business time geographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states percentage total company sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition merck operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time available information company internet website address wwwmerckcom company available free charge investor portion website annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec address website wwwsecgov addition company provide charge copy annual report include financial statement schedule write request shareholder office secretary merck inc galloping hill road kenilworth usa companys corporate governance guideline charter board director stand committee available company website wwwmerckcomcompanyoverviewleadership information available print shareholder request company item risk factor summary risk factor company subject number risk realize materially adversely affect business result operation cash flow financial condition prospect follow summary principal risk factor face company company dependent patent right patent right invalidate circumvent business materially adversely affect company product lose market exclusivity company generally experience significant rapid loss sale product table content key product generate significant company profit cash flow event adversely affect market lead product material adverse effect company result operation financial condition company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection company success dependent successful development marketing new product subject substantial risk company face continue pricing pressure respect product uncertainty global economic condition costreduction measure take certain government negatively affect company operating result company face intense competition low cost generic product company face intense competition competitor product global covid pandemic adverse impact company business operation financial performance company unable predict extent covid pandemic future pandemic epidemic similar public health threat adversely impact business operation financial performance result operation financial condition company significant global operation expose additional risk adverse event material adverse effect company result operation financial condition failure attract retain highly qualified personnel affect company ability successfully develop commercialize product past company experience difficulty delay manufacture certain product include vaccine company able realize expect benefit investment emerge market company expose market risk fluctuation currency exchange rate interest rate pharmaceutical product develop unexpected safety efficacy concern reliance thirdparty relationship outsource arrangement materially adversely affect company business negative event animal health industry material adverse effect future result operation financial condition biologic vaccine carry unique risk uncertainty material adverse effect company future result operation financial condition health care industry united states continue subject increase regulation political action company product include product development market company obtain maintain regulatory approval development follow regulatory approval adversely affect sale company product company subject variety international law regulation table content company subject evolve complex tax law result additional liability affect result operation financial condition product liability insurance product limit cost prohibitive unavailable company increasingly dependent sophisticated software application compute infrastructure cloud service provider company experience network cyberattack lead disruption worldwide operation include manufacture research sale operation company target future cyberattack social medium platform present risk challenge propose spinoff organon complete term timeline currently contemplate achieve expect result cost complete propose spinoff significant addition company unable achieve strategic financial benefit expect achieve spinoff organon follow spinoff price share companys common stock fluctuate significantly significant income tax liability spinoff certain relate transaction determine taxable federal income tax purpose list exhaustive company face additional challenge risk investor carefully consider information set forth include follow risk factor decide invest company security risk factor risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation cash flow prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result risk relate company business company dependent patent right patent right invalidate circumvent business materially adversely affect patent protection consider aggregate material importance company market human health animal health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent claim party infringement company company defend patent outside united state include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic pharmaceutical product time time file abbreviate nda fda seek market generic form company product prior expiration relevant patent own license company company normally respond defend patent include filing lawsuit allege patent table content infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case thirdparty patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency circumstance diminish eliminate sale profit region negatively affect company result operation court decision relate company patent potential legislation united state certain foreign market relate patent regulatory initiative result general weaken intellectual property protection important product lose patent protection profitable market sale product likely decline significantly result generic version product available company result operation adversely affect lost sale company launch commercially successful product replace lose sale addition product measure fair value capitalize connection acquisition experience difficulty market negatively affect product cash flow company recognize material noncash impairment charge respect value product chart list patent protection certain company market product patent protection candidate phase clinical development set forth item business patent trademark license company product lose market exclusivity company generally experience significant rapid loss sale product company depend patent provide exclusive marketing right product period time loss patent protection company product typically lead significant rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss market exclusivity material adverse effect company business cash flow result operation financial condition prospect example patent provide market exclusivity nuvare expire april generic competition begin december company experience rapid substantial decline nuvare sale result generic competition addition januvia janumet lose market exclusivity united states january januvia lose market exclusivity september finally spc provide market exclusivity janumet expire april company anticipate sale januvia janumet market decline substantially loss market exclusivity key product generate significant company profit cash flow event adversely affect market lead product material adverse effect company result operation financial condition company ability generate profit operate cash flow depend largely continue profitability company key product keytruda gardasilgardasil januvia janumet bridion particular company oncology portfolio lead keytruda represent vast majority company revenue growth result company dependence key product event adversely affect product market product significant adverse impact result operation cash flow event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect result postapproval trial increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale product table content company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection order remain competitive company like major pharmaceutical company continue launch new product expect decline sale product loss market exclusivity mean company future success dependent pipeline new product include new product develop collaboration joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research development process new drug vaccine result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result compete product manufacturer reach market clinical trial new drug successful new drug effective harmful effect new drug approve regulator intend use possible obtain patent new drug payer refuse cover reimburse new product sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial condition prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market fail succeed numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication anticipate labeling uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval failure certain market obtain reimbursement commensurate level innovation clinical benefit present product lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right table content future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection acquisition certain collaboration failure successfully develop market new product short term long term material adverse effect company business result operation cash flow financial condition prospect company face continue pricing pressure respect product company face continue pricing pressure globally particularly mature market manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act aca iii state activity aim increase price transparency include new law note item competition health care environment change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure addition united states large customer receive high rebate drug certain highly competitive category company compete place formulary manage care organization exclusion product formulary lead reduce usage manage care organization order provide information company pricing practice company annually post website pricing transparency report united states report provide company average annual list price net price increase company portfolio date company gross sale reduce result rebate discount return outside united states numerous major market include japan china pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine furthermore government order reprice specific product determine use product exceed certain threshold define applicable repricing rule governmentmandate price reduction occur april expect impact company product company expect pricing pressure continue future uncertainty global economic condition costreduction measure take certain government negatively affect company operating result uncertainty global economic geopolitical condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial condition prospect discuss competition health care environment global effort health care cost containment continue exert pressure product pricing market access worldwide change health care system health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market government mandate pricing action reduce price generic patent drug addition company revenue performance negatively affect costreduction measure take government thirdpartie low health care cost company anticipate action additional action future continue negatively affect revenue performance table content credit economic condition worsen result economic currency impact affect market globally material adverse effect company result company face intense competition low cost generic product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak united states united states political pressure reduce spending prescription drug lead legislation measure encourage use generic biosimilar product company policy actively protect patent right generic challenge company product arise time company patent prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial condition prospect company face intense competition competitor product company product face intense competition competitor product competition increase new product enter market event competitor product safer effective convenient use well insurance coverage reimbursement level effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial condition prospect addition product measure fair value capitalize connection acquisition experience difficulty market negatively impact product cash flow company recognize material noncash impairment charge respect value product global covid pandemic adverse impact company business operation financial performance company unable predict extent covid pandemic future pandemic epidemic similar public health threat adversely impact business operation financial performance result operation financial condition company business financial result negatively impact outbreak covid continue duration severity covid pandemic uncertain rapidly change difficult predict degree covid impact company result depend future development company knowledge control include limited duration outbreak severity success action take contain prevent virus treat impact quickly extent normal economic operating condition resume covid pandemic impact company business numerous way expect company human health business revenue negatively impact reduce access health care provider give social distancing measure negatively affect vaccine oncology sale particular estimate overall negative impact covid pandemic merck revenue year approximately billion largely attributable pharmaceutical segment approximately million attributable animal health segment roughly twothird merck pharmaceutical segment revenue comprise physicianadministered product despite strong underlie demand affect social distancing measure few visit delay elective surgery covid pandemic impact prioritization covid patient health care provider result reduced administration company human health product particular vaccine include gardasil keytruda implanon table content nexplanon addition decline elective surgery negatively affect demand bridion sale pneumovax increase heighten awareness pneumococcal vaccination merck believe global health system patient largely adapt impact covid company assumption ongoe residual negative impact persist particularly half notably respect vaccine sale impact expect acute united states year merck assume unfavorable impact revenue approximately covid pandemic relate pharmaceutical segment sale addition year respect covid pandemic merck expect net negative impact operating expense spend development covid antiviral program expect exceed favorable impact low spending area covid pandemic despite company effort manage impact ultimate impact depend factor company knowledge control include duration covid virus governmental thirdparty action take contain prevent spread treat virus mitigate public health economic effect addition future pandemic epidemic similar public health threat present similar risk company business cash flow result operation financial condition prospect company significant global operation expose additional risk adverse event material adverse effect company result operation financial condition extent company operation outside united states significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement include imposition trade sanction similar restriction united states government foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease failure attract retain highly qualified personnel affect company ability successfully develop commercialize product company success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical research development governmental regulation commercialization competition qualified personnel pharmaceutical industry intense company sure able attract retain quality personnel cost materially increase past company experience difficulty delay manufacture certain product include vaccine merck past experienced difficulty manufacture certain product include vaccine example company issue product recall zerbaxa follow identification product sterility issue company future experience difficulty delay manufacture product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead table content manufacturing shutdown product shortage delay product manufacture delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply addition company experience difficulty delay manufacturing product cause natural disaster hurricane manufacturing difficulty result product shortage lead lose sale reputational harm company company able realize expect benefit investment emerge market company take step increase sale emerge market guarantee company effort expand sale market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company successfully implement emerge market strategy attract retain qualified personnel company require increase reliance thirdparty agent develop market addition country currency fluctuate substantially currency devalue company offset devaluation company financial performance country adversely affect company business china grow rapidly past year importance china company overall pharmaceutical vaccine business outside united states increase accordingly continue growth company business china dependent ongoing development favorable environment innovative pharmaceutical product vaccine sustain access company currently market product absence trade impediment adverse pricing control note competition health care environment pricing pressure china increase chinese government take step reduce cost include implement health care reform lead acceleration generic substitution available chinese government update nrdl time year mechanism drug add list evolve inclusion require price negotiation impact outlook market select brand drug add nrdl doubledigit price reduction pricing pressure exist china health care reform increase pressure acceleration generic substitution government vbp program government implement vbp program tendering process mature product generic substitute generic quality consistency evaluation approval mature product enter round vbp average price reduction company expect vbp semiannual process significant impact mature product move forward addition company anticipate report inquiry governmental authority involve multinational pharmaceutical company china continue reason sale emerge market carry significant risk time macroeconomic growth select emerge market expect outpace europe united states lead significant increase headcount spending country access innovative medicine patient failure maintain company presence emerge market material adverse effect company business cash flow result operation financial condition prospect company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter business development transaction borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate inflation negatively affect company business cash flow result operation financial condition prospect table content order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option forwards interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful certain company interest rate derivative investment base london interbank offer rate libor portion merck indebtedness bear interest variable interest rate primarily base libor libor subject recent national international regulatory guidance proposal reform cause libor cease exist entirely future company expect reasonable alternative libor implement prior termination company predict consequence timing development include increase interest expense require amendment contract reference libor pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action reliance thirdparty relationship outsource arrangement materially adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company thirdparty service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business negative event animal health industry material adverse effect future result operation financial condition future sale key animal health product adversely affect number risk factor include certain risk specific animal health business example outbreak disease carry animal african swine fever lead widespread death precautionary destruction reduce consumption demand animal adversely affect company result operation outbreak highly contagious disease near company main production site require company immediately halt manufacture animal health product site force company incur substantial expense procure raw material product risk specific animal health include epidemic pandemic government procurement pricing practice weather global agribusiness economic event animal health segment company business significant impact event future result operation significant biologic vaccine carry unique risk uncertainty material adverse effect company future result operation financial condition successful development testing manufacturing commercialization biologic vaccine particularly human animal health vaccine long complex expensive uncertain process unique risk uncertaintie relate biologic vaccine include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction united states result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost table content development manufacturing marketing biologic vaccine subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example united states bla include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval generally require release manufacture commercial lot manufacture biologic vaccine especially large quantity complex require use innovative technology handle living microorganism lot approve biologic vaccine undergo thorough testing identity strength quality purity potency manufacturing biologic require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company required provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic vaccine frequently costly manufacture production ingredient derive live animal plant material biologic vaccine synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead variability manufacturing process lead allegation harm include infection allergic reaction allegation review standard investigation process lead closure product facility possible contamination event result substantial cost risk relate government regulation legal proceeding health care industry united states continue subject increase regulation political action discuss competition health care environment company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider executive branch congress state legislature united states enact major health care reform legislation form aca insurance market reform advance state federal insurance exchange launch aca increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program aca require pharmaceutical manufacturer pay cost medicine include biosimilar product medicare beneficiary medicare coverage gap socalle donut hole company revenue reduce approximately million requirement pharmaceutical manufacturer require pay annual nontax deductible health care reform fee company record million cost annual fee february center medicare medicaid services cms issue medicaid rebate final rule implement provision aca effective april rule provide comprehensive guidance calculation average manufacturer price good price metric utilize determine rebate drug manufacturer require pay state medicaid program recently cms previously decline define constitute product line extension statutory definition cms issue new rule december significantly expand definition term line extension january include broad range product include product reflect new strength dosage form release mechanism route administration expand definition increase number drug subject high medicaid rebate effective january final rule change way manufacturer calculate good price relation certain patient support program include coupon result increase table content company medicaid rebate impact provision final rule adversely impact company business cash flow result operation financial condition prospect discuss competition health care environment november department health human service office inspector general oig issue final rule effective january eliminate antikickback statute safe harbor rebate pay medicare plans pbms behalf plan company anticipate effect change way currently contract new framework significantly alter way business plan sponsor pbms behalf plan november cms issue mfn rule intend effective january institute new pricing system certain prescription drug biologic product cover medicare medicare reimburse favor nation price mean low price adjust volume difference gross domestic product reimburse product include keytruda sell member country oecd use current average sale price aspbase payment framework certain physicianadministere drug implementation mfn rule material adverse effect company business cash flow result operation financial condition prospect fda recently issue rulemaking allow commercial importation certain prescription drug canada fdaauthorize time limited program sponsor states native american tribe recognize rule certain future circumstance pharmacist wholesaler fda recently release final guidance industry detail procedure drug manufacturer import fdaapprove prescription drug biological combination product manufacture abroad authorize intend sale foreign country change effective material adverse effect company business cash flow result operation financial condition prospect organization include trade group merck member file suit challenge mfn rule lawsuit remain pende preliminary injunction enter case trade organization merck member bring suit pende federal district court challenge commercial importation rule company predict likelihood regulation effective additional future change health care industry general pharmaceutical industry particular occur change material adverse effect company business cash flow result operations financial condition prospect company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include japan china united states fda administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case reduction cost drug fda foreign regulatory authority include japan china substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent selling product jurisdiction company able realize revenue new product jurisdiction approval table content development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval decrease demand company product include follow result postapproval phase trial study rereview product market recall loss marketing approval product market change government standard public expectation safety efficacy quality labeling change scrutiny advertising promotion past clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pmda chinas nmpa increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim civil criminal governmental action relate product research andor marketing activity addition dissemination promotional material evolve digital channel serve increase visibility scrutiny marketplace company subject variety international law regulation company currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business cash flow result operation financial condition prospect company law regulation include additional health care reform initiatives united states country include additional mandatory discount fee foreign corrupt practice act antibribery corruption law iii new law regulation judicial governmental decision affect pricing drug reimbursement access marketing jurisdiction change intellectual property law change accounting standard new increase datum privacy regulation enforcement particularly united states vii legislative mandate preference local manufacturing pharmaceutical vaccine product viii emerge new global regulatory requirement report payment value transfer health care professional environmental regulation potential impact importation restriction embargo trade sanction legislative andor regulatory change table content company subject evolve complex tax law result additional liability affect result operation financial condition company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return periodically examine tax authority company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue addition company negatively affect change tax law new tax law affect example tax rate andor revise tax law interpretation domestic foreign jurisdiction product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost insurance increase significantly company subject substantial number product liability claim item financial statement supplementary datum note contingency environmental liability information company current product liability litigation respect product liability company selfinsure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise risk relate technology company increasingly dependent sophisticated software application compute infrastructure company experience network cyberattack lead disruption worldwide operation include manufacture research sale operation company target future cyberattack company increasingly dependent sophisticated software application complex information technology system compute infrastructure cloud service provider collectively system conduct critical operation certain system manage host provide party assist conduct company business disruption degradation manipulation system intentional accidental mean company employee party authorize access unauthorized party adversely affect key business process cyberattack company system thirdparty provider system cloudbase system result exposure confidential information modification critical datum andor failure critical operation misuse system result disclosure sensitive personal information theft trade secret intellectual property confidential business information company continue leverage new innovative technology enterprise improve efficacy efficiency business process use create new risk company experience network cyberattack lead disruption worldwide operation include manufacture research sale operation result loss company implement variety measure enhance modernize system guard similar attack future pursue enterprisewide effort enhance company resiliency future cyberattack include incident similar attack objective effort protect future cyberattack improve speed company recovery attack enable continued business operation great extent possible recovery period aggregate impact cyberattack network disruption include cyberattack company operation financial condition material date company continue target event nature expect continue company monitor datum information technology personnel usage company system reduce risk continue ongoing table content basis current potential threat assurance company effort protect datum system efforts thirdparty provider protect system successful prevent disruption companys operation include manufacture research sale operation disruption past future result loss revenue loss critical sensitive information company company thirdparty provider database system past future result financial legal business reputational harm company substantial remediation cost social medium platform present risk challenge inappropriate andor unauthorized use certain social medium channel cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information addition negative inaccurate post comment company product social networking platform damage company reputation brand image goodwill disclosure nonpublic companysensitive information company workforce external medium channel lead information loss internal company social medium policy guide employee appropriate personal professional use social medium company process place completely secure protect information identify new point entry social medium continue expand present new challenge risk relate propose spinoff organon propose spinoff organon complete term timeline currently contemplate achieve expect result february company announce intention spinoff product women health biosimilar establish brand business new independent publicly trade company name organon organon distribution organon publicly trade stock company shareholder distribution expect qualify taxfree company shareholder federal income tax purpose transaction expect complete late second quarter completion spinoff subject number factor condition assurance company able complete spinoff term timeline announce unanticipated development delay prevent adversely affect propose spinoff include limited disruption general financial market condition potential problem delay obtain regulatory tax approval clearance addition consummation propose spinoff require final approval company board director cost complete propose spinoff significant addition company unable achieve strategic financial benefit expect achieve spinoff organon company incur significant expense connection spinoff addition company able achieve strategic financial benefit expect result spinoff anticipate benefit spinoff base number assumption prove incorrect follow spinoff price share companys common stock fluctuate significantly company predict effect spinoff trading price share common stock market value share common stock equal great market value share common stock prior spinoff addition price merck common stock volatile time spinoff significant income tax liability spinoff certain relate transaction determine taxable federal income tax purpose company expect prior completion spinoff receive opinion tax counsel conclude thing spinoff outstanding organon share merck table content shareholder certain relate transaction qualify taxfree merck shareholder section internal revenue code extent cash receive lieu fractional share organon common stock opinion bind internal revenue service irs accordingly company believe risk low irs reach conclusion respect spinoff different conclusion reach opinion opinion rely certain fact assumption representation undertaking merck organon past future conduct company respective business matter incomplete incorrect satisfied alter conclusion party giving opinion propose spinoff ultimately determine taxable company believe unlikely spinoff treat taxable dividend merck shareholder federal income tax purpose merck shareholder incur significant federal income tax liability addition merck recognize taxable gain extent fair market value organon common stock exceed merck tax basis stock date spinoff cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning negative variation forego identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval product potential development program include statement relate expect impact covid pandemic carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic andor biosimilar product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general impact global covid pandemic future pandemic epidemic similar public health threat company business operation financial performance change government law regulation include law govern intellectual property enforcement thereof affect company business table content efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant change customer relationship change behavior spend pattern purchaser health care product service include delay medical procedure ration prescription medication reduce frequency physician visit forego health care insurance coverage legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product cyberattack company thirdparty provider information technology system disrupt company operation lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state united states require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate propose spinoff delay cost complete spinoff significant expect list consider exhaustive statement potential risk uncertainty risk factor item unresolved staff comment item property companys corporate headquarter currently locate kenilworth new jersey company previously announce intend consolidate new jersey campuse single corporate headquarters location rahway new jersey end company maintain operational divisional headquarters kenilworth new jersey madison new jersey upper gwynedd pennsylvania principal research facility locate rahway kenilworth new jersey west point pennsylvania boston massachusetts south san francisco california elkhorn nebraska animal health principal research facility outside united states locate united kingdom switzerland china mercks manufacturing operation currently headquarter whitehouse station new jersey company production facility human health product location united states puerto rico outside united states subsidiary company own interest manufacturing plant property japan singapore south africa countries western europe central south america asia number property transfer organon spinoff capital expenditure billion billion billion united states amount billion billion billion abroad expenditure amount billion billion billion table content company subsidiarie principal facility manufacturing plant title consider satisfactory company believe property good operating condition machinery equipment maintain company believe plant manufacture product suitable intend purpose capacity project capacity include previouslydisclose capital expansion project adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference item financial statement supplementary datum note contingency environmental liability item safety disclosure applicable table content executive officer registrant age february officer list serve pleasure board director officer elect pursuant arrangement understand officer person age office business experience kenneth frazier chairman president chief executive officer december sanat chattopadhyay executive vice president president merck manufacturing division march frank clyburn executive vice president chief commercial officer january president global oncology business unit october december robert davis executive vice president global services chief financial officer april executive vice president chief financial officer april april richard deluca executive vice president president merck animal health september michael fleme senior vice president chief ethic compliance officer march senior vice president international legal compliance january march vice president international legal compliance july january julie gerberde executive vice president chief patient officer strategic communication global public policy population health july executive vice president strategic communication global public policy population health january july rita karachun senior vice president finance global controller march dean president merck research laboratory january senior vice president discovery sciences translational medicine merck research laboratory november january vice president translational medicine march november prior chief scientific officer associate vice president university utah health sciences steven mizell executive vice president chief human resource officer december executive vice president human resource monsanto company august december michael nally executive vice president chief marketing officer january president global vaccines global human health september january managing director united kingdom ireland global human health january september jennifer zachary executive vice president general counsel corporate secretary january executive vice president general counsel april january partner covington burling llp january march february merck announce kenneth frazier chairman chief executive officer retire chief executive officer effective june frazier continue serve merck board director executive chairman transition period determine board merck board director unanimously elect robert davis merck current executive vice president global services chief financial officer chief executive officer member board effective july davis president merck effective april time company operate divisionshuman health animal health manufacturing merck research laboratorieswill begin report davis table content item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk january approximately shareholder record company common stock issuer purchase equity security month end december follow issuer purchase equity security millions total number average price approximate dollar value share share pay purchase period purchase share plan programs october october november november december december total company purchase share month end december plan approve board director october purchase billion merck share treasury table content performance graph follow graph assume investment december reinvestment dividend companys common share index composite peer group major europeanbase pharmaceutical company abbvie inc amgen inc astrazeneca plc bristolmyers squibb company johnson johnson eli lilly company glaxosmithkline plc novartis pfizer inc roche holding sanofi comparison fiveyear cumulative total return merck inc composite peer group index end period value cagr merck peer grp merck peer grp compound annual growth rate peer group average calculate market cap weight basis performance graph deem incorporate reference file security act securities exchange act extent company specifically incorporate reference addition performance graph deem soliciting material file sec subject regulation provide regulation liabilities section securities exchange act extent company specifically request information treat soliciting material specifically incorporate reference filing security act exchange act table content item management discussion analysis financial condition result operation follow section generally discuss result yeartoyear comparison discussion result yeartoyear comparison include find management discussion analysis financial condition result operation item company annual report fiscal year end december file february description mercks business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operate segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer company previously healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company divest remain business segment quarter company previously alliance segment primarily include activity company relationship astrazeneca relate sale nexium prilosec conclude plan spinoff women health biosimilar establish brand new company february merck announce intention spinoff product women health biosimilar establish brand business new independent publicly trade company name organon organon distribution organon publicly trade stock company shareholder distribution expect qualify taxfree company shareholder federal income tax purpose establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product include zetia vytorin rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan organon development capability initially focus latestage development lifecycle management expect time develop research capability select therapeutic area spinoff expect complete late second quarter subject market certain condition table content overview financial highlight change exclude foreign million change exchange sale net income attributable merck inc nongaap net income attributable merck inc earning common share assume dilution attributable merck inc common shareholder nongaap earning common share assume dilution attributable merck inc common shareholder nongaap net income nongaap earning share eps exclude acquisition divestiturerelate cost restructure cost certain item discussion reconciliation gaap nongaap net income eps nongaap income nongaap eps executive summary worldwide sale billion increase compare exclude unfavorable effect foreign exchange sale increase drive primarily oncology certain hospital acute care product animal health growth area largely offset negative effect coronavirus disease covid pandemic discuss effect generic competition particularly diversify brand women health franchise competitive pressure virology franchise pricing pressure diabete franchise merck continue execute strategic priority report yearoveryear sale growth despite business challenge pose covid pandemic roughly twothird merck pharmaceutical segment revenue comprise physicianadministere product sale negatively affect patient inability access health care provider few visit social distancing measure year company experience partial recovery underlie demand product key growth pillar despite pandemic merck employee organization continue important work enrol maintain clinical study progress pipeline ensure supply patient access company portfolio medically important medicine vaccine company execute merck capital allocation priority complete business development transaction invest pipeline additionally company remain track complete spinoff organon late second quarter create company focus strength portfolio allow pursue respective market opportunity business strategy product comprise organon total sale billion merck actively monitor business development landscape growth opportunity meet company strategic criterion expand oncology presence merck complete acquisition arqule inc arqule biopharmaceutical company focus kinase inhibitor discovery development treatment cancer disease velosbio inc velosbio clinicalstage biopharmaceutical company commit develop firstinclass cancer therapy target receptor tyrosine kinaselike orphan receptor ror currently evaluate treatment patient hematologic malignancy solid tumor additionally merck enter strategic collaboration agreement seagen gain access ladiratuzumab vedotin investigational antibody drug conjugate target liv tukysa tucatinib small molecule tyrosine kinase inhibitor treatment human epidermal growth factor receptor herpositive cancer augment mercks animal health business company acquire right sentinel flavor tabs sentinel spectrum chew industrywide effort develop solution pandemic company acquire oncoimmune company develop therapeutic candidate treatment patient hospitalize covid themis bioscience gmbh themis company focus vaccine immunemodulation therapie infectious disease include covid vaccine candidate additionally merck enter table content strategic collaboration ridgeback biotherapeutic ridgeback bio develop orally available antiviral candidate clinical development treatment patient covid international aids vaccine initiative inc iavi develop investigational vaccine sarscov study prevention covid january company announce discontinuing development covid vaccine candidate note consolidated financial statement company receive numerous regulatory approval oncology keytruda receive approval united states monotherapy therapeutic area cutaneous squamous cell carcinoma cscc metastatic microsatellite instabilityhigh msih mismatch repair deficient dmmr colorectal cancer nonmuscle invasive bladder cancer nmibc tumor mutational burdenhigh tmbh solid tumor combination chemotherapy treatment triplenegative breast cancer tnbc merck receive approval united states week dose regiman adult indication additionally keytruda receive approval china treatment certain patient head neck squamous cell carcinoma hnscc china japan treatment certain patient esophageal squamous cell carcinoma escc lynparza develop collaboration astrazeneca plc astrazeneca receive approval united states combination bevacizumab firstline maintenance treatment certain adult patient advance epithelial ovarian fallopian tube primary peritoneal cancer complete partial response firstline platinumbase chemotherapy treatment certain adult patient metastatic castrationresistant prostate cancer mcrpc follow progression prior treatment additionally lynparza approve european union monotherapy treatment adult patient mcrpc brca mutation progress follow prior therapy maintenance treatment certain adult patient metastatic adenocarcinoma pancrea lynparza approve japan treatment type advanced cancer ovarian prostate pancreatic cancer lenvima develop collaboration eisai ltd eisai receive approval china monotherapy treatment differentiate thyroid cancer gardasil approve use woman girl japan market silgard additionally food drug administration fda grant accelerated approval expand indication gardasil prevention oropharyngeal head neck cancer cause certain hpv type january company receive fda approval verquvo vericiguat reduce risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous diuretic adult verquvo jointly develop bayer bayer addition recent regulatory approval discuss company advanced latestage pipeline regulatory submission keytruda review united states andor internationally treatment certain patient tnbc classical hodgkin lymphoma chl colorectal cancer cscc esophageal gastric cancer lenvima review japan monotherapy treatment thymic cancer investigational valent pneumococcal conjugate vaccine priority review fda prevention invasive pneumococcal disease adult year age old european medicine agency ema review application licensure adult company involve litigation challenge validity pfizer inc patent relate pneumococcal vaccine technology united states foreign jurisdiction company phase oncology program include keytruda therapeutic area biliary tract cervical cutaneous squamous cell endometrial gastric hepatocellular mesothelioma ovarian prostate smallcell lung cancer lynparza monotherapy colorectal cancer combination keytruda nonsmallcell lung smallcell lung cancer lenvima combination keytruda bladder endometrial gastric head neck melanoma non smallcell lung cancer oncology belzutifan investigational hypoxiainducible factor alpha hif inhibitor evaluate treatment patient von hippellindau diseaseassociate renal cell carcinoma rcc receive breakthrough therapy designation fda additionally company candidate phase clinical development therapeutic area include gefapixant selective nonnarcotic orally administer investigational pxreceptor antagonist develop treatment refractory chronic cough investigational treatment patient hospitalize covid mka islatravir investigational nucleoside reverse transcriptase translocation inhibitor nrtti combination doravirine treatment hiv infection evaluate prevention pneumococcal disease pediatric patient table content company allocate resource support commercial opportunity near term make necessary investment support long term growth research development expense reflect high cost relate business development activity high clinical development spending increase investment discovery research early drug development november mercks board director approve increase company quarterly dividend raising share share company outstanding common stock company return billion shareholder dividend share repurchase management february merck announce kenneth frazier chairman chief executive officer retire chief executive officer effective june frazier continue serve merck board director executive chairman transition period determine board merck board director unanimously elect robert davis merck current executive vice president global services chief financial officer chief executive officer member board effective july davis president merck effective april time company operate divisionshuman health animal health manufacturing merck research laboratory mrlwill begin report davis covid overall response covid pandemic merck remain focused protect safety employee ensure supply medicine vaccine reach patient contribute scientific expertise development antiviral approach support health care provider merck community covidrelated disruption patient ability access health care provider negatively affect result merck remain confident fundamental underlie demand product prospect longterm growth estimate negative impact covid pandemic merck sale approximately billion largely attributable pharmaceutical segment approximately million attributable animal health segment roughly twothird merck pharmaceutical segment revenue comprise physicianadministered product despite strong underlie demand affect social distancing measure few visit delay elective surgery covid pandemic impact prioritization covid patient health care provider result reduced administration company human health product particular vaccine include gardasil keytruda implanonnexplanon addition decline elective surgery negatively affect demand bridion sale pneumovax increase heighten awareness pneumococcal vaccination operating expense positively affect approximately million primarily lower promotional selling cost low research development expense net investment covidrelate antiviral vaccine research program merck believe global health system patient largely adapt impact covid company assumption ongoe residual negative impact persist particularly half notably respect vaccine sale impact expect acute united states year merck assume unfavorable impact revenue approximately covid pandemic relate pharmaceutical segment sale addition year respect covid pandemic merck expect net negative impact operating expense spend development covid antiviral program expect exceed favorable impact low spending area covid pandemic pricing global effort health care cost containment continue exert pressure product pricing market access worldwide change health care system health care reform increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary contribute pricing pressure international market governmentmandate pricing action reduce price generic patent drug addition company revenue performance negatively table content affect costreduction measure take government thirdpartie low health care cost company anticipate action additional action future continue negatively affect revenue performance operating result sale change change exclude foreign exclude foreign million change exchange change exchange united states international total plus international equal total round worldwide sale grow high sale oncology franchise reflect strong growth keytruda increase alliance revenue lynparza lenvima contribute revenue growth high sale certain vaccine include gardasilgardasil pneumovax increase sale certain hospital acute care product include prevymis bridion high sale animal health product drive revenue growth sale growth partially offset effect generic competition certain product include women health product nuvare hospital acute care product noxafil cubicin oncology product emendemend injection cardiovascular product zetia vytorin product diversified brand franchise particularly singulair diversified brand franchise include certain product approach expiration marketing exclusivity long protect patent develop market low sale pediatric vaccine include proquad mmr varivax low sale diabete product januvia janumet virology product zepati isentressisentress partially offset revenue growth discuss covid pandemic negatively affect sale sale united states grew primarily drive high sale keytruda increase alliance revenue lynparza lenvima high sale animal health product revenue growth largely offset low sale nuvare januvia noxafil emendemend injection mmr janumet varivax implanonnexplanon international sale grow increase international sale primarily reflect growth keytruda gardasilgardasil increase alliance revenue lynparza high sale pneumovax prevymis januvia animal health product sale growth partially offset low sale zepati vytorin noxafil zetia remicade emendemend injection product diversified brand franchise particularly singulair nasonex international sale represent total sale note consolidated financial statement detail sale company product discussion performance select product franchise follow pharmaceutical segment oncology change exclude change foreign exclude foreign million change exchange change exchange keytruda alliance revenue lynparza alliance revenue lenvima emend alliance revenue represent merck share profit product sale net cost sale commercialization cost note consolidated financial statement table content keytruda antipd program death receptor therapy approve monotherapy treatment certain patient cervical cancer chl cscc escc gastric gastroesophageal junction adenocarcinoma hnscc hepatocellular carcinoma hcc nonsmallcell lung cancer nsclc smallcell lung cancer sclc melanoma merkel cell carcinoma msih dmmr cancer include msihdmmr colorectal cancer primary mediastinal large bcell lymphoma pmbcl tmbh cancer urothelial carcinoma include nmibc keytruda approve treatment certain patient combination chemotherapy metastatic squamous nonsquamous nsclc combination chemotherapy hnscc combination chemotherapy tnbc combination axitinib rcc combination lenvima endometrial carcinoma keytruda clinical development program include study broad range cancer type global sale keytruda grew drive high demand company continue launch keytruda multiple new indication globally covid pandemic dampen effect grow demand sale united state continue build multiple approve indication particular treatment advanced nsclc monotherapy combination chemotherapy nonsquamous squamous metastatic nsclc uptake rcc adjuvant melanoma hnscc bladder cancer endometrial carcinoma indication uptake week adult dose regiman united states benefit sale keytruda sale growth international market drive continued uptake approve indication particularly sale growth partially offset decline japan price pursuant repricing rule japanese government reduce price keytruda effective february additionally keytruda subject price reduction april provision japanese pricing rule january fda approve keytruda monotherapy treatment certain patient bacillus calmetteguerin bcgunresponsive highrisk nmibc base result keynote trial april fda grant accelerated approval additional recommend dosage week keytruda adult indication include monotherapy combination therapy new dosage option available addition current dose week june fda grant accelerated approval keytruda monotherapy treatment adult pediatric patient unresectable metastatic tmbh solid tumor determine fdaapprove test progress follow prior treatment satisfactory alternative treatment option base result keynote trial june fda approve keytruda monotherapy treatment patient recurrent metastatic cscc curable surgery radiation base datum keynote trial additionally june fda approve keytruda monotherapy firstline treatment patient unresectable metastatic msih dmmr colorectal cancer base result keynote trial october fda approve expand label keytruda monotherapy treatment adult patient relapse refractory chl base result keynote trial fda approve update pediatric indication keytruda treatment pediatric patient refractory chl chl relapse line therapy keytruda previously approve fda accelerate approval process treatment adult pediatric patient refractory chl relapse prior line therapy base datum keynote trial accordance accelerate approval regulation continue approval contingent verification description clinical benefit accelerate approval requirement fulfil datum keynote november fda grant accelerate approval keytruda combination chemotherapy treatment patient locally recurrent unresectable metastatic tnbc tumor express pdl combine positive score cp determine fdaapproved test approval base result keynote trial june keytruda approve national medical product administration nmpa china monotherapy secondline treatment patient locally advanced metastatic escc table content tumor express pdl cp indication grant base keynote trial include data extension global study chinese patient december chinas nmpa approve keytruda monotherapy firstline treatment patient metastatic unresectable recurrent hnscc tumor express pdl cp determine fully validate test august keytruda approve japans pharmaceuticals medical devices agency pmda monotherapy treatment patient tumor pdlpositive radically unresectable advanced recurrent escc progress chemotherapy approval base result keynote trial additionally keytruda approve japans pmda use additional recommend dosage include monotherapy combination therapy new dosage option available addition current dose january keytruda approve european commission firstline treatment adult patient msih dmmr colorectal cancer base result keynote study company party certain thirdparty license agreement pursuant company pay royalty sale keytruda term significant agreement merck pay royalty worldwide sale keytruda party royalty decline terminate company pay additional royalty worldwide sale keytruda party termination date vary country royalty expire united states major european market royalty include cost sale lynparza oral poly adpribose polymerase parp inhibitor develop collaboration astrazeneca note consolidated financial statement approve treatment certain type advance ovarian breast pancreatic prostate cancer alliance revenue relate lynparza grow continued uptake multiple approve indication united states china japan fda approve lynparza combination bevacizumab firstline maintenance treatment certain adult patient advance epithelial ovarian fallopian tube primary peritoneal cancer complete partial response firstline platinumbase chemotherapy november lynparza approve maintenance treatment adult patient advance highgrade epithelial ovarian fallopian tube primary peritoneal cancer complete partial response follow completion firstline platinumbase chemotherapy combination bevacizumab cancer associate homologous recombination deficiency hrdpositive status approval base result paola trial fda approve lynparza treatment adult patient deleterious suspect deleterious germline somatic homologous recombination repair hrr genemutate mcrpc progress follow prior treatment november lynparza approve monotherapy treatment adult patient mcrpc brca mutations germline andor somatic progress follow prior therapy approval base result profound trial july lynparza approve monotherapy maintenance treatment adult patient germline brca mutation metastatic adenocarcinoma pancrea progress firstline chemotherapy regimen approval base result polo trial december lynparza approve japan treatment type advanced cancer ovarian prostate pancreatic cancer approval authorize lynparza use maintenance treatment firstline chemotherapy contain bevacizumab genetical recombination patient hrd ovarian cancer treatment patient brca genemutate brcam mcrpc maintenance treatment platinumbase chemotherapy patient brcam curatively unresectable pancreas cancer concurrent approval japanese ministry health labor welfare base result paola profound polo trial lenvima oral receptor tyrosine kinase inhibitor develop collaboration eisai note consolidated financial statement approve treatment certain type thyroid cancer hcc combination everolimus certain patient rcc combination keytruda table content treatment certain patient endometrial carcinoma alliance revenue relate lenvima grow high demand united states china november chinas nmpa approve lenvima monotherapy treatment differentiate thyroid cancer global sale emend prevention certain chemotherapyinduced nausea vomiting decline primarily low demand pricing united states generic competition emend injection follow patent expiry september contribute emend sale decline low demand japan result generic competition oral formulation emend follow loss market exclusivity december respectively market exclusivity oral formulation emend previously expire april fda approve koselugo selumetinib treatment pediatric patient year age old neurofibromatosis type symptomatic inoperable plexiform neurofibromas fda approval base positive result national cancer institute nci cancer therapy evaluation program ctepsponsore phase sprint stratum trial coordinated ncis center cancer research pediatric oncology branch regulatory approval medicine treatment rare debilitate genetic condition koselugo jointly develop commercialize astrazeneca globally note consolidated financial statement vaccine change exclude change foreign exclude foreign million change exchange change exchange gardasilgardasil proquad mmr varivax pneumovax worldwide sale gardasilgardasil vaccine help prevent certain cancer disease cause certain type hpv grow primarily high volume china replenishment dose borrow center disease control prevention cdc pediatric vaccine stockpile replenishment result recognition sale million combine reduction sale million borrowing result favorable impact sale million low demand united states hong kong sar prc attributable covid pandemic partially offset increase sale gardasilgardasil june fda approve expand indication gardasil prevention oropharyngeal head neck cancer cause hpv type oropharyngeal head neck cancer indication approve accelerate approval base effectiveness prevent hpvrelate anogenital disease july gardasil approve pmda japan use woman girl year old prevention cervical cancer certain cervical vaginal vulvar precancer genital wart cause hpv type cover vaccine december silgard approve japan prevention anal cancer precursor lesion cause hpv type individual year old genital wart man year old gardasil market japan silgard company party certain thirdparty license agreement pursuant company pay royalty sale gardasilgardasil term significant agreement merck pay royalty worldwide sale gardasilgardasil party royalty obligation agreement expire december additional royalty sale gardasilgardasil united states party royalty obligation expire december royalty include cost sale table content global sale proquad pediatric combination vaccine help protect measle mump rubella varicella declined drive primarily low demand united state result few measle outbreak compare couple unfavorable impact covid pandemic partially offset high pricing worldwide sale mmr vaccine help protect measle mump rubella declined drive primarily low demand united state result few measle outbreak compare couple unfavorable impact covid pandemic low demand brazil contribute mmr sale decline global sale varivax vaccine help prevent chickenpox varicella declined drive primarily low demand united states result covid pandemic partially offset high pricing varivax sale decline attributable low government tender brazil worldwide sale pneumovax vaccine help prevent pneumococcal disease grow primarily high volume united states attributable heighten awareness pneumococcal vaccination high pricing united states contribute pneumovax sale growth hospital acute care change change exclude foreign exclude foreign million change exchange change exchange bridion noxafil prevymis cubicin zerbaxa global sale bridion reversal type neuromuscular block agent surgery grow high demand globally particularly united states few elective surgery result covid pandemic unfavorably affect demand worldwide sale noxafil antifungal agent prevention certain invasive fungal infection decline generic competition united states patent provide market exclusivity certain form noxafil represent majority noxafil sale expire july additionally patent noxafil expire number major european market december result company experience volume pricing decline noxafil sales market result generic competition expect decline continue worldwide sale prevymis medicine prophylaxis prevention cytomegalovirus cmv infection disease adult cmvseropositive recipient allogenic hematopoietic stem cell transplant grow continued uptake launch united states prevymis approve january fda november global sale cubicin injection antibiotic treatment certain bacterial infection decline primarily ongoing generic competition united states december company temporarily suspend sale zerbaxa combination antibacterial betalactamase inhibitor treatment certain bacterial infection subsequently issue product recall follow identification product sterility issue result company record intangible asset impairment charge relate zerbaxa note consolidated financial statement company anticipate zerbaxa return market june fda approve supplemental new drug application nda recarbrio imipenem cilastatin relebactam treatment patient year age old hospitalacquire table content bacterial pneumonia ventilatorassociate bacterial pneumonia cause certain susceptible gramnegative microorganism immunology change change exclude foreign exclude foreign million change exchange change exchange simponi remicade sale simponi oncemonthly subcutaneous treatment certain inflammatory disease market company europe russia turkey nearly flat sale simponi unfavorably affected launch biosimilar compete product company expect competition continue unfavorably affect sale simponi sale remicade treatment inflammatory disease market company europe russia turkey declined drive ongoing biosimilar competition company marketing territory europe company lose market exclusivity remicade major european market long market exclusivity marketing territory company experience pricing volume decline market result biosimilar competition expect decline continue company marketing right respect product revert janssen pharmaceuticals inc second half virology change exclude change foreign exclude foreign million change exchange change exchange isentressisentress zepatier worldwide sale isentressisentress hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection decline primarily competitive pressure united states company expect competitive pressure isentressisentress continue global sale zepati treatment adult patient chronic hepatitis virus genotype infection decline drive low demand globally competition decline patient volume couple impact covid pandemic cardiovascular change change exclude foreign exclude foreign million change exchange change exchange zetiavytorin atozet rosuzet alliance revenue adempas adempas alliance revenue represent merck share profit sale bayer marketing territory product sale net cost sale commercialization cost note consolidated financial statement combine global sale zetia market country outside united states ezetrol vytorin market outside united states inegy medicine lower ldl cholesterol decline drive primarily low sale ezetrol japan ezetrol inegy patent provide market exclusivity ezetrol japan expire september generic competition begin june table content patent ezetrol inegy expire april april respectively accordingly company experience sale decline market result generic competition expect decline continue sale decline attributable low pricing follow loss exclusivity australia high demand ezetrol china partially offset sale decline merck lose market exclusivity united states zetia vytorin subsequently lose nearly sale product result generic competition sale atozet market outside united states medicine lower ldl cholesterol grew primarily drive high demand market particularly japan countries asia pacific region zetia vytorin atozet rosuzet contribute organon connection spinoff note consolidated financial statement adempas cardiovascular drug treatment pulmonary arterial hypertension worldwide collaboration bayer market develop soluble guanylate cyclase sgc modulator include adempas note consolidated financial statement revenue adempas include merck share profit sale adempas bayer marketing territory grow sale merck marketing territory grow january fda approve verquvo vericiguat sgc stimulator reduce risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous diuretic adult symptomatic chronic heart failure reduce ejection fraction approval base result pivotal phase victoria trial follow priority regulatory review verquvo worldwide clinical development collaboration bayer include adempas reference diabete change change exclude foreign exclude foreign million change exchange change exchange januviajanumet worldwide combine sale januvia janumet medicine help lower blood sugar level adult type diabete decline result continued pricing pressure united states partially offset high demand certain international market particularly china company expect pricing pressure continue januvia janumet lose market exclusivity united states january supplementary patent certificate provide market exclusivity januvia janumet expire september april respectively company anticipate sale januvia janumet market decline substantially loss market exclusivity women health change exclude change foreign exclude foreign million change exchange change exchange implanonnexplanon nuvare worldwide sale implanonnexplanon singlerod subdermal contraceptive implant decline primarily drive low demand united states result covid pandemic worldwide sale nuvare vaginal contraceptive product decline generic competition united states patent provide market exclusivity nuvare expire april generic competition begin december accordingly company experience rapid substantial decline nuvare sale expect decline continue table content implanonnexplanon nuvare contribute organon connection spinoff note consolidated financial statement biosimilar change change exclude foreign exclude foreign million change exchange change exchange biosimilar calculation meaningful biosimilar product market company pursuant agreement samsung bioepis ltd samsung develop commercialize multiple prespecified biosimilar candidate currently company market renflexis infliximababda biosimilar remicade infliximab treatment certain inflammatory disease ontruzant trastuzumabdttb biosimilar herceptin trastuzumab treatment herpositive breast cancer overexpresse gastric cancer brenzys etanercept biosimilar biosimilar enbrel treatment certain inflammatory disease aybintio bevacizumab treatment certain type cancer merck commercialization territory agreement vary product sale growth biosimilar primarily continued postlaunch uptake renflexis united states canada launch ontruzant brazil august grant marketing authorization aybintio treatment metastatic carcinoma colon rectum metastatic breast cancer nsclc advanced andor metastatic rcc epithelial ovarian fallopian tube primary peritoneal cancer cervical cancer application seek approval aybintio united states file september biosimilar product contribute organon connection spinoff note consolidated financial statement animal health segment change change exclude foreign exclude foreign million change exchange change exchange livestock companion animal sale livestock product grow predominantly additional month sale relate april acquisition antelliq leader digital animal identification traceability monitoring solution note consolidated financial statement sale companion animal product grew drive primarily high demand bravecto line product parasitic control high demand companion animal vaccine cost expense million change change cost sale sell general administrative research development restructuring cost income expense net calculation meaningful table content cost sale cost sale billion compare billion cost sale include amortization intangible asset record connection acquisition collaboration license arrangement total billion compare billion respectively additionally cost include intangible asset impairment charge billion million relate market product intangible note consolidated financial statement company recognize additional impairment charge future relate intangible asset measure fair value capitalize connection business acquisition charge material cost include charge million connection discontinuation covid vaccine development program note consolidated financial statement inventory writeoff million relate recall zerbaxa note consolidated financial statement include cost sale expense associate restructuring activity amount million compare million primarily reflect accelerated depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss gross margin compare gross margin decline reflect unfavorable effect high impairment charge note pricing pressure charge relate discontinuation covid vaccine development program high inventory writeoff relate recall zerbaxa note partially offset favorable effect product mix low amortization intangible asset low restructuring cost sell general administrative selling general administrative sga expense billion decline compare decline drive primarily low administrative sell promotional cost include low travel meeting expense covid pandemic favorable effect foreign exchange partially offset high cost relate spinoff organon contribution merck foundation sga expense include million cost relate spinoff organon sga expense include restructure cost million million respectively relate primarily accelerate depreciation facility close divest separation cost associate sale force reduction incur reflect restructure cost discuss research development research development expense billion increase compare increase drive primarily high upfront payment relate acquisition collaboration include billion charge relate acquisition velosbio note consolidated financial statement high expense relate clinical development increase investment discovery research early drug development high restructuring cost contribute increase expense increase expense partially offset low inprocess research development iprd impairment charge low cost result covid pandemic net spending covid relate vaccine antiviral research program expense comprise cost directly incur mrl company research development division focus human health relate activity billion compare billion include expense animal health research cost license cost cost incur division support activity include depreciation production general administrative aggregate billion billion additionally expense include billion charge acquisition velosbio note million charge acquisition oncoimmune charge million relate transaction seagen expense include million charge acquisition peloton note consolidated financial statement information transaction expense include iprd impairment charge million million respectively note consolidated financial statement company recognize additional impairment charge future relate cancellation delay pipeline program measure fair value capitalize connection business acquisition table content charge material addition expense include million cost associate restructuring activity primarily relate accelerated depreciation expense include expense income relate change estimate fair value measurement liability contingent consideration record connection business acquisition company record net reduction expense million million respectively relate change estimate restructure cost early merck approve new global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint program continuation company plant rationalization build prior restructure program include action associate plan spinoff organon company continue evaluate global footprint overall operating model subsequently identify additional action restructure program identify action time action currently contemplate restructure program expect substantially complete end cumulative pretax cost incur company implement program estimate approximately billion company expect record charge approximately million related restructuring program company anticipate action restructure program result annual net cost saving approximately million end action previous global restructuring program substantially complete restructure cost primarily represent separation relate cost associate restructuring activity million million separation cost incur associate actual headcount reduction estimate expense exist severance program headcount reduction probable reasonably estimate include restructuring cost asset abandonment facility shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include cost sale sell general administrative expense research development cost company record aggregate pretax cost million million related restructuring program activity note consolidated financial statement income expense net income expense net million income compare million expense primarily high income investment equity security net largely related moderna inc detail component income expense net note consolidated financial statement segment profit million pharmaceutical segment profit animal health segment profit nonreportable segment profit income taxis pharmaceutical segment profit comprise segment sale standard cost sga expense directly incur segment animal health segment profit comprise segment sale cost sale sga expense directly incur segment internal management reporting present chief operating decision maker merck allocate remain cost sale include segment profit describe research development expense incur mrl general administrative expense cost financing activity separate division maintain responsibility table content monitor manage cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit cost related restructuring activity acquisition divestiturerelated cost include amortization purchase accounting adjustment intangible asset impairment charge change estimate fair value measurement liability contingent consideration additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale pharmaceutical segment profit grew compare drive primarily high sale lower sell promotional cost animal health segment profit grew drive primarily high sale low promotional selling cost partially offset high cost unfavorable effect foreign exchange taxis income effective income tax rate reflect impact acquisition divestiturerelated cost restructure cost partially offset beneficial impact foreign earning include product mix effective income tax rate reflect unfavorable impact charge acquisition velosbio tax benefit recognize effective income tax rate reflect favorable impact million net tax benefit relate settlement certain federal income tax matter note consolidated financial statement reversal tax reserve establish connection divestiture merck consumer care mcc business lapse statute limitation addition effective income tax rate reflect unfavorable impact charge acquisition peloton tax benefit recognize charge million relate finalization treasury regulation transition tax associate enactment tax legislation know tax cut job act tcja note consolidated financial statement net income loss attributable noncontrolle interest net income loss attributable noncontrolle interest million compare million loss drive primarily portion goodwill impairment charge relate certain business healthcare service segment attributable noncontrolle interest net income earning common share net income attributable merck inc billion billion eps nongaap income nongaap ep nongaap income nongaap ep alternative view company performance merck provide management believe information enhance investor understand company result permit investor understand management assess performance nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consider nonrecurre consist acquisition divestiturerelate cost restructure cost certain item exclude item significant component understand assess financial performance nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap eps management use measure internally plan forecasting purpose measure performance company metric addition senior management annual compensation derive nongaap pretax income nongaap income nongaap ep measure determine accordance gaap standardize mean prescribed gaap comparable calculation similar measure company information nongaap income nongaap eps consider addition substitute superior net income ep prepared accordance generally accept accounting principle united states gaap table content reconciliation gaap financial measure nongaap financial measure follow million share amount income taxis report gaap increase decrease exclude item acquisition divestiturerelated cost restructure cost item charge acquisition velosbio charge formation collaboration charge acquisition oncoimmune charge discontinuation covid vaccine development program charge acquisition peloton charge relate termination collaboration samsung charge acquisition viralytic limited nongaap income taxis tax income report gaap estimate tax benefit exclude item adjustment tax benefit record conjunction cubist pharmaceuticals inc acquisition net tax benefit settlement certain federal income tax matter tax benefit reversal tax reserve relate divestiture mcc net tax charge relate finalization treasury regulation relate enactment tcja nongaap taxes income nongaap net income net income loss attributable noncontrolle interest report gaap acquisition divestiturerelate cost attributable noncontrolle interest nongaap net income attributable noncontrolle interest nongaap net income attributable merck inc eps assume dilution report gaap ep difference nongaap ep assume dilution include billion intangible asset impairment charge relate zerbaxa include million intangible asset impairment charge relate sivextro note consolidated financial statement include million relate transaction seagen note consolidated financial statement represent charge formation collaboration eisai note consolidated financial statement estimate tax impact exclude item determine apply statutory rate originate territory nongaap adjustment acquisition divestiturerelated cost nongaap income nongaap eps exclude impact certain amount record connection business acquisition divestiture amount include amortization intangible asset amortization purchase accounting adjustment inventory intangible asset impairment charge expense income relate change estimate fair value measurement liability contingent consideration exclude integration transaction certain cost associate business acquisition divestiture restructure cost nongaap income nongaap eps exclude cost relate restructuring action note consolidated financial statement amount include employee separation cost accelerate depreciation table content associate facilities close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action restructure cost include asset abandonment facility shutdown relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan share base compensation cost certain item item adjusted evaluate individual basis consider quantitative qualitative aspect typically consist item unusual nature significant result particular period indicative future operating result exclude nongaap income nongaap eps charge acquisition velosbio oncoimmune charge relate collaboration include transaction seagen note consolidated financial statement charge discontinuation covid vaccine development program adjustment tax benefit record conjunction cubist pharmaceuticals inc acquisition exclude nongaap income nongaap eps charge acquisition peloton note consolidated financial statement tax charge relate finalization treasury regulation relate tcja net tax benefit relate settlement certain federal income tax matter tax benefit relate reversal tax reserve establish connection divestiture mcc note consolidated financial statement exclude nongaap income nongaap eps charge relate formation collaboration eisai note consolidated financial statement charge relate termination collaboration agreement samsung insulin glargine note consolidated financial statement charge acquisition viralytic note consolidated financial statement measurementperiod adjustment relate provisional amount record tcja note consolidated financial statement begin company change treatment certain item purpose nongaap report historically merck non gaap result exclude amortization intangible asset recognize connection business acquisition reflect acquisition divestiture relate cost exclude amortization intangible originate collaboration asset acquisition licensing arrangement begin merck nongaap result long differentiate nature intangible asset amortize exclude amortization intangible asset begin merck nongaap result exclude gain loss investment equity security prior period amount recast conform new presentation research development research pipeline company currently candidate regulatory review united states internationally latestage clinical development chart reflect company current research pipeline february relate discussion set forth item business research development acquire inprocess research development connection business acquisition company record fair value inprocess research project time acquisition reach technological feasibility december balance iprd billion note consolidated financial statement iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally certain iprd program fail abandon development company realize future cash flow estimate record iprd table content acquisition date circumstance occur company future operating result adversely affect company recognize impairment charge charge material company record iprd impairment charge research development expense million million million respectively note consolidated financial statement additional research development require remain program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval acquisition research collaboration license agreement merck continue remain focused pursue opportunity potential drive near longterm growth certain recent transaction summarize additional detail include note consolidated financial statement merck actively monitor landscape growth opportunity meet company strategic criterion january merck acquire arqule publicly trade biopharmaceutical company focus kinase inhibitor discovery development treatment patient cancer disease billion arqule lead investigational candidate arq novel oral bruton tyrosine kinase btk inhibitor currently evaluate treatment bcell malignancy transaction account acquisition business company record iprd billion relate goodwill million net liability million july merck ridgeback bio closely hold biotechnology company close collaboration agreement develop molnupiravir know eidd orally available antiviral candidate clinical development treatment patient covid merck gain exclusive worldwide right develop commercialize molnupiravir relate molecule term agreement ridgeback bio receive upfront payment eligible receive future contingent payment dependent achievement certain developmental regulatory approval milestone share net profit molnupiravir relate molecule approve molnupiravir currently evaluate phase clinical trial hospital outpatient setting primary completion date phase study june company anticipate interim efficacy datum quarter september merck seagen announce oncology collaboration globally develop commercialize seagens ladiratuzumab vedotin investigational antibodydrug conjugate target liv currently phase clinical trial breast cancer solid tumor term agreement merck upfront payment million billion equity investment million share seagen common stock price share merck record million research development expense relate transaction seagen eligible receive future contingent milestone payment dependent achievement certain developmental salesbase milestone concurrent transaction seagen grant merck exclusive license commercialize tukysa tucatinib small molecule tyrosine kinase inhibitor treatment herpositive cancer asia middle east latin america region outside united states canada europe term agreement merck upfront payment aggregate million record research development expense seagen eligible receive future contingent regulatory approval milestone tiere royalty base annual sale level tukysa merck territory december merck acquire oncoimmune privately hold clinicalstage biopharmaceutical company upfront payment million addition oncoimmune shareholder eligible receive future contingent regulatory approval milestone payment tiere royalty oncoimmune lead therapeutic candidate know cdfc evaluate treatment patient hospitalize covid topline result pre plan interim efficacy analysis phase study release september result phase study consistent topline result receive february submit publication future transaction account table content acquisition asset agreement prior completion acquisition oncoimmune spunout certain right asset unrelated program new entity own exist shareholder oncoimmune connection closing acquisition merck invest million ownership interest new entity value million result million premium merck recognize net liability million company record research development expense million relate transaction december merck announce enter agreement government support development manufacture initial distribution approval emergency use authorization eua fda june agreement merck receive approximately million manufacturing supply approximately dose government june help meet government pandemic response goal follow execution agreement merck receive feedback fda additional datum study conduct oncoimmune need support potential eua application base fda feedback merck long expect supply government half merck actively work fda address agencys comment december merck acquire velosbio privately hold clinicalstage biopharmaceutical company billion velosbio lead investigational candidate know vls antibodydrug conjugate target receptor tyrosine kinaselike orphan receptor ror currently evaluate treatment patient hematologic malignancy solid tumor transaction account acquisition asset merck record net asset million primarily cash research development expense billion relate transaction february merck pandion therapeutics inc pandion enter definitive agreement merck acquire pandion clinical stage biotechnology company develop novel therapeutic design address unmet need patient live autoimmune disease share cash represent approximate total equity value billion pandion advance pipeline precision immune modulator target critical immune control node term acquisition agreement merck subsidiary initiate tender offer acquire outstanding share pandion close tender offer subject certain condition include tender share represent majority total number pandion share fully diluted common stock expiration waiting period hartscottrodino antitrust improvement act customary condition transaction expect close half capital expenditure capital expenditure billion billion billion expenditure united states billion billion billion increase capital expenditure reflect investment new capital project focus primarily increase manufacturing capacity merck key product increase capital expenditure reflect purchase manufacturing facility dunboyne ireland support upcoming product launch note consolidated financial statement company plan invest billion new capital project depreciation expense billion billion billion billion billion billion relate location united states total depreciation expense include accelerate depreciation million million respectively associate restructuring activity note consolidated financial statement table content analysis liquidity capital resource merck strong financial profile enable fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operation total debt decline work capital compare primarily relate increase shortterm debt support funding business development activity capital expenditure cash provide operating activity billion compare billion reflect high payment relate collaboration billion compare million cash provide operating activity continue company primary source fund finance operating need capital expenditure treasury stock purchase dividend pay shareholder cash investing activity billion compare billion increase drive primarily low proceed sale security investment high use cash acquisition high capital expenditure partially offset low purchase security investment cash financing activity billion compare billion low use cash financing activity drive primarily net increase shortterm borrowing compare net decrease shortterm borrowing low purchase treasury stock partially offset high payment debt low proceed issuance debt high dividend pay shareholder low proceed exercise stock option company account receivable factoring agreement financial institution certain country sell account receivable note consolidated financial statement company factor billion billion account receivable fourth quarter respectively factor arrangement reduce outstanding account receivable cash receive financial institution report operating activity consolidate statement cash flow certain factoring arrangement ease administration company collect customer payment relate factored receivables remit financial institution december company collect million million respectively behalf financial institution remit january respectively net cash flow collection report financing activity consolidate statement cash flow table content company contractual obligation december follow payment period million total purchase obligation loan payable current portion longterm debt longterm debt interest relate debt obligation unrecognize tax benefit transition tax relate enactment tcja milestone payment relate collaboration lease include future inventory purchase company commit connection certain divestiture december company consolidated balance sheet reflect liability unrecognize tax benefit include interest penalty billion include million reflect current liability high degree uncertainty time future cash outflow liability unrecognize tax benefit year reasonable estimate period cash settlement year connection enactment tcja company require pay onetime transition tax company elect pay period year permit tcja note consolidated financial statement reflect payment collaborative agreement salesbase milestone achieve deem contractual obligation pay note consolidated financial statement amount exclude reasonably certain lease renewal execute note consolidated financial statement purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising amount include contingent milestone payment relate collaborative arrangement acquisition consider contractual obligation successful achievement developmental regulatory approval commercial milestone december company recognize liability contingent salesbase milestone payment relate collaboration astrazeneca eisai payment remain subject achievement relate sale milestone aggregate billion note consolidated financial statement exclude research development obligation potential future funding commitment approximately million investment research venture capital fund loan payable current portion longterm debt reflect million longdate note subject repayment option holder require funding obligation relate company pension postretirement benefit plan expect material company currently anticipate contribute approximately million pension plan million international pension plan million postretirement benefit plan june company issue billion principal senior unsecured note consist billion note billion note billion note billion note merck net proceed offer general corporate purpose include limitation repayment outstanding commercial paper borrowing indebtedness upcoming maturity march company issue billion principal senior unsecured note consist million note billion note billion note billion note company net proceed offer general corporate purpose include repayment outstanding commercial paper borrowing company billion credit facility mature june facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility table content march company file security registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date company continue maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november mercks board director declare quarterly dividend share company outstanding common stock pay january january board director declare quarterly dividend share company common stock second quarter payable april october mercks board director authorize purchase billion merck common stock treasury treasury stock purchase authorization time limit time openmarket transaction block transaction exchange privately negotiate transaction company spend billion purchase million share common stock treasury program march company temporarily suspend share repurchase program december company remain share repurchase authorization billion company purchase billion billion common stock respectively authorize share repurchase program company enter accelerated share repurchase asr agreement thirdparty financial institution dealer asr agreement merck agree purchase billion merck common stock total initial delivery million share merck common stock base thencurrent market price dealer merck payment billion merck dealer fund exist cash investment shortterm borrowing settlement asr agreement merck receive additional million share determine average daily volume weightedaverage price merck common stock term asr program negotiate discount bring total share receive merck program million financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective company foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause change foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year table content future company layer hedge time increase portion forecast sale hedge get close expect date forecast sale portion forecast sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning comprehensive income loss oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge unrealize gain loss contract record accumulate comprehensive income loss aoci reclassify sale hedge anticipate revenue recognize derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose merck principally sell foreign currency revenue hedging program uniform weaken dollar yield large overall potential loss market value hedge instrument market value merck hedge decline estimate million million december respectively uniform weaken dollar market value determine foreign exchange option pricing model hold factor exchange rate constant predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar company manage operating activity net asset position local subsidiary order mitigate effect exchange monetary asset liability company use balance sheet risk management program mitigate exposure net monetary asset denominate currency subsidiary functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument cash flow contract report operating activity consolidate statement cash flow sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly weaken currency exposure company december income taxis decline approximately million million respectively company net short payable position relative major foreign currency consideration forward contract uniform weaken dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow economy argentina determine hyperinflationary consequently accordance gaap company begin remeasure monetary asset liability operation earning impact company result immaterial company use forward exchange contract hedge portion net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation unrealize gain loss contract record foreign currency translation adjustment oci remain aoci sale complete substantially complete liquidation subsidiary company exclude certain portion change fair value derivative table content instrument assessment hedge effectiveness exclude component change fair value exclude component recognize oci company recognize earning initial value exclude component straightline basis life derivative instrument marktomarket approach cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table million number interest rate total swap notional debt instrument par value debt swap hold note note note interest rate swap mature january interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change swap contract cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value merck investment debt change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion billion respectively percentage point decrease december negatively affect net aggregate market value billion billion respectively fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting estimate companys consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include table content produce preparation product launch amount record contingency environmental liability accrual contingent salesbase milestone payment reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement acquisition disposition determine transaction account acquisition disposal asset business company make certain judgment include assessment input process output associate acquire set activity company determine substantially fair value gross asset include transaction concentrate single asset group similar asset asset represent business consider business asset transaction need include input substantive process significantly contribute ability create output business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency generally recognize fair value fair value determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition fair value intangible asset include acquire iprd determine utilize information available near acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination thenuseful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization certain company business acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probability weight cash flow subsequent acquisition date report period contingency resolve contingent consideration liability remeasure current fair value change expense income record earning change input result significantly different fair value adjustment judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize table content product extent time potential new product introduction company competitor life asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate company determine transaction account acquisition business transaction account asset acquisition business combination goodwill record asset acquisition acquire iprd alternative future use charge expense contingent consideration recognize acquisition date instance product development milestone recognize achievement salesbase milestone recognize milestone deem probable company achieve revenue recognition recognition revenue require evidence contract probable collection sale proceed completion substantially performance obligation merck act principal substantially customer arrangement record revenue gross basis majority company contract relate pharmaceutical animal health segment single performance obligation promise transfer good shipping consider immaterial context overall customer arrangement damage loss good transit rare shipping deem separately recognize performance obligation vast majority revenue sale product recognize point time control good transfer customer company determine title risk reward ownership transfer customer company entitle payment certain service animal health segment revenue recognize time generally ratably contract term service provide service revenue material nature company business gives rise type variable consideration include discount return estimate time sale generally expect value method likely method prompt pay discount united states sale discount issue customer pointofsale intermediary wholesaler know chargeback form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount collection account receivable expect excess year provision aggregate customer discount cover chargeback rebate chargeback discount occur contract customer purchase intermediary wholesaler contract customer generally purchase product wholesaler contract price plus markup wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider company use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision amount accrue aggregate customer discount evaluate quarterly table content basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue company continually monitor provision aggregate customer discount material adjustment estimate associate aggregate customer discount provision summarize information change aggregate customer discount accrual relate sale follow million balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december outside united states variable consideration form discount rebate combination commerciallydriven discount highly competitive product class discount require gain maintain reimbursement legislatively mandate rebate certain european country legislatively mandate rebate calculate base estimate government total unbudgeted spending company specific payback obligation rebate require base specific product sale threshold company apply estimate factor actual invoice sale represent expect level future discount rebate obligation associate sale company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market generic competition change formulary launch overthecounter product product return provision pharmaceutical sale percentage net pharmaceutical sale outside united states return allow certain country limit basis merck payment term pharmaceutical customer typically day receipt invoice animal health customer typically day receipt invoice certain product include keytruda long payment term day outside united states payment term typically day day certain market long payment term distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return wholesaler generally provide abovementioned datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return table content inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december million million respectively contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include governmental environmental matter note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify accrue cost past merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually table content company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million december liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option total pretax sharebase compensation expense million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weightedaverage period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan net periodic benefit cost pension plan total million million million net periodic benefit credit postretirement benefit plan million million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset change net periodic benefit cost year year pension plan largely attributable change discount rate affect net loss amortization company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come discount rate company pension postretirement benefit plan range december compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum current market condition actual return company plan asset reference information company develop forwardlooke return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan range compare range company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard table content deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact company net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact merck net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net loss amount primarily reflect difference expect actual return plan asset effect change actuarial assumption record component aoci expect return pension plan base calculate marketrelated value asset net loss amount aoci excess certain threshold amortize net periodic benefit cost average remain service life employee restructure cost restructure cost record connection restructuring program design streamline company cost structure result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place accrue termination cost company recognize range cost good estimate range range well estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect cost sale sell general administrative expense research development expense depend nature asset impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macroeconomic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price company conclude likely fair value report unit carrying quantitative fair value test perform carrying value report unit great fair value goodwill impairment charge record difference carry value goodwill table content acquire intangible asset exclude iprd initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd company acquire conjunction acquisition business represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company evaluate iprd impairment annually frequently impairment indicator exist perform quantitative test compare fair value iprd intangible asset carry value impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize operating result judgment evaluate impairment longlive intangible materially affect company result operation impairment investment company review investment marketable debt security impairment base determination decline market value investment carrying value otherthantemporary company consider available evidence evaluate potential impairment investment marketable debt security include duration extent fair value cost change fair value consider temporary report net tax oci otherthantemporary impairment occur company expect recover entire amortize cost basis marketable debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci investment publicly trade equity security report fair value determine quote market price active market identical asset quote price similar asset input observable corroborate observable market datum change fair value include income expense net investment equity security readily determinable fair value record cost plus minus subsequent observable price change orderly transaction identical similar investment minus impairment adjustment recognize income expense net realize gain loss equity security include income expense net taxis income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operate estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement table content financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement recently issue accounting standard discussion recently issue accounting standard note consolidated financial statement cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning negative variation forego identify fact relate strictly historical current fact statement likely address company growth strategy financial result product approval product potential development program include statement relate expect impact covid pandemic carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income comprehensive income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck inc subsidiary year end december millions share amount sale cost expense cost sale sell general administrative research development restructuring cost income expense net income taxis tax income net income net income loss attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder consolidate statement comprehensive income merck inc subsidiary year end december million net income attributable merck inc comprehensive loss net taxis net unrealized loss gain derivative net reclassification net unrealized loss gain investment net reclassification benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment comprehensive income attributable merck inc accompany note integral consolidated financial statement table content consolidate balance sheet merck inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account inventory exclude inventory classify asset note current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability merck inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck inc adoption new accounting standard comprehensive loss net taxis cash dividend declare common stock share treasury stock share purchase net loss attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive loss net taxis cash dividend declare common stock share treasury stock share purchase net loss attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive loss net taxis cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity amortization depreciation intangible asset impairment charge charge acquisition velosbio inc charge acquisition peloton therapeutics inc charge future payment relate collaboration license option defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase seagen inc common stock purchase security investment proceed sale security investment acquisition velosbio inc net cash acquire acquisition arqule inc net cash acquire acquisition antelliq corporation net cash acquire acquisition peloton therapeutics inc net cash acquire acquisition net cash acquire net cash provide investing activity cash flow financing activity net change shortterm borrowing payment debt proceed issuance debt purchase treasury stock dividend pay stockholder proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent restrict cash net decrease increase cash cash equivalent restrict cash cash cash equivalent restrict cash beginning year includes restrict cash january include asset note cash cash equivalent restrict cash end year includes restrict cash december include asset note accompany note integral consolidated financial statement table content note consolidated financial statement merck inc subsidiarie million share amount nature operation merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product company operation principally manage product basis include operate segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer company previously healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company divest remain business segment quarter company previously alliance segment primarily include activity company relationship astrazeneca relate sale nexium prilosec conclude plan spinoff women health biosimilar establish brand new company february merck announce intention spinoff product women health biosimilar establish brand business new independent publicly trade company name organon organon distribution organon publicly trade stock company shareholder distribution expect qualify taxfree company shareholder federal income tax purpose establish brand include transaction consist dermatology nonopioid pain management respiratory select cardiovascular product include zetia vytorin rest merck diversify brand franchise merck exist research pipeline program continue own develop merck plan organon development capability initially focus latestage development lifecycle management expect time develop research capability select therapeutic area spinoff expect complete late second quarter subject market certain condition subsequent spinoff historical result women health biosimilar establish brand business reflect discontinued operation company consolidate financial statement summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate table content company significant influence control interest interest entity own equally company party share control carry equity basis acquisition business combination acquisition method accounting require asset acquire liability assume record date acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency generally recognize fair value fair value determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record asset acquisition acquire inprocess research development iprd alternative future use charge expense contingent consideration recognize acquisition date foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include accumulate comprehensive income loss aoci reflect separate component equity subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost net realizable value cost substantial majority pharmaceutical vaccine inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstin firstout fifo method inventory consist currently market product certain inventory produce preparation product launch consider high probability regulatory approval evaluate recoverability inventory produce preparation product launch company consider likelihood revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt security classify availableforsale report fair value fair value company investment marketable debt security determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability change fair value consider temporary report net tax comprehensive income oci company consider available evidence evaluate potential impairment investment marketable debt security include duration extent fair value cost thantemporary impairment occur company expect recover entire amortize cost basis marketable debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute credit loss remain portion otherthantemporary impairment relate table content factor recognize oci realize gain loss debt security include income expense net investment publicly trade equity security report fair value determine quote market price active market identical asset quote price similar asset input observable corroborate observable market datum change fair value include income expense net investment equity security readily determinable fair value record cost plus minus subsequent observable price change orderly transaction identical similar investment minus impairment adjustment recognize income expense net realize gain loss equity security include income expense net revenue recognition recognition revenue require evidence contract probable collection sale proceed completion substantially performance obligation merck act principal substantially customer arrangement record revenue gross basis majority company contract relate pharmaceutical animal health segment single performance obligation promise transfer good shipping consider immaterial context overall customer arrangement damage loss good transit rare shipping deem separately recognize performance obligation vast majority revenue sale product recognize point time control good transfer customer company determine title risk reward ownership transfer customer company entitle payment company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile interpretation allow company recognize revenue sale vaccine government stockpile sale meet criterion revenue recognition accounting guidance certain service animal health segment revenue recognize time generally ratably contract term service provide service revenue material nature company business gives rise type variable consideration include discount return estimate time sale generally expect value method likely method prompt pay discount united states sale discount issue customer pointofsale intermediary wholesaler know chargeback form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount collection account receivable expect excess year provision aggregate customer discount cover chargeback rebate billion billion billion chargeback discount occur contract customer purchase intermediary wholesaler contract customer generally purchase product wholesaler contract price plus markup wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider company use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision amount accrue aggregate customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue accrue balance relative provision chargeback rebate include account receivable accrue current liability table content million billion respectively december million billion respectively december outside united states variable consideration form discount rebate combination commerciallydriven discount highly competitive product class discount require gain maintain reimbursement legislatively mandate rebate certain european country legislatively mandate rebate calculate base estimate government total unbudgeted spending company specific payback obligation rebate require base specific product sale threshold company apply estimate factor actual invoice sale represent expect level future discount rebate obligation associate sale company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market generic competition change formulary launch overthecounter product outside united states return allow certain country limit basis merck payment term pharmaceutical customer typically day receipt invoice animal health customer typically day receipt invoice certain product include keytruda long payment term day outside united states payment term typically day day certain market long payment term note disaggregate revenue disclosure depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing depreciation expense billion billion billion advertising promotion cost advertising promotion cost expense incur company record advertising promotion expense billion billion billion software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development cost include property plant equipment addition company capitalize certain cost incur implement cloud computing arrangement consider service agreement include asset capitalize software cost amortize period range year long lives generally associate enterprisewide project implement multiple year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business acquire goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform carrying value report unit great fair value goodwill impairment charge record difference carry value goodwill acquire intangible acquire intangible include product product right license trade name patent initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year note company periodically evaluate current fact circumstance indicate carry value acquire intangible recoverable circumstance determine exist estimate undiscounte table content future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference carry value intangible asset fair value determine base net present value estimate future cash flow acquire inprocess research development iprd company acquire conjunction acquisition business represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination thenuseful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization company evaluate iprd impairment annually frequently impairment indicator exist perform quantitative test compare fair value iprd intangible asset carrying value fair value carrying impairment loss recognize operating result contingent consideration certain company acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale transaction account acquisition business fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingency resolve contingent consideration liability remeasure current fair value change expense income record earning significant event increase decrease probability achieve development regulatory milestone increase decrease project cash flow result correspond increase decrease fair value relate contingent consideration obligation transaction account acquisition asset business contingent consideration recognize acquisition date instance product development milestone recognize achievement salesbase milestone recognize milestone deem probable company achieve research development research development expense incur nonrefundable advance payment good service future research development activity expense activity perform good receive payment research development expense include restructure cost iprd impairment charge addition research development expense include expense income relate change estimate fair value measurement liability contingent consideration research development expense include upfront milestone payment relate asset acquisition licensing transaction involve clinical development program receive regulatory approval collaborative arrangement merck enter collaborative arrangement provide company vary right develop produce market product collaborative partner merck principal sale transaction party company recognize sale cost sale sell general administrative expense gross basis profit sharing amount pay collaborative partner record cost sale collaborative partner principal sale transaction party company record profit sharing amount receive collaborative partner alliance revenue sale alliance revenue record net cost sale include adjustment share commercialization cost partner accordance collaboration agreement adjustment determine compare commercialization cost merck incur directly report sell general administrative expense cost collaborative partner incur research development cost merck incur relate collaboration record research development expense cost reimbursement collaborative partner payment receive collaborative partner share cost pursuant term collaboration agreement record increase decrease research development expense table content addition term collaboration agreement require company payment base achievement certain developmental regulatory approval commercial milestone upfront milestone payment payable merck collaborative partner prior regulatory approval expense incur include research development expense payment collaborative partner subsequent regulatory approval capitalize amortize estimate useful life correspond intangible asset cost sale provide future cash flow support amount capitalize salesbased milestone payable merck collaborative partner accrue capitalize subject cumulative amortization catchup probable achieve amortization catchup calculate time regulatory approval indication unapproved time collaboration form time formation collaboration approve product relate intangible asset recognize amortize cost sale remain useful life subject impairment testing sharebase compensation company expense sharebased payment employee requisite service period base grantdate fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement employee termination cost accrue restructuring action probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income company account tax effect tax global intangible lowtaxed income gilti certain foreign subsidiary income tax provision period tax arise use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection acquisition include initial fair value determination asset liability primarily iprd intangible asset contingent consideration subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability accrual contingent salesbase milestone payment reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation table content recently adopt accounting standard june financial accounting standard board fasb issue new guidance accounting credit loss financial instrument new guidance introduce expect loss model estimate credit loss replace incur loss model new guidance change impairment model availableforsale debt security require use allowance record estimate credit loss subsequent recovery company adopt new guidance effective january impact company consolidate financial statement adoption november fasb issue new guidance collaborative arrangement intend reduce diversity practice clarify certain transaction collaborative arrangement participant account revenue recognition guidance asc company retrospectively adopt new guidance effective january result minor change presentation information relate company collaborative arrangement note note december fasb issue amend guidance accounting reporting income taxis guidance intend simplify accounting income taxis remove exception relate certain intraperiod tax allocation defer tax liability clarify guidance primarily related evaluate stepup tax basis goodwill business combination reflect enact change tax law rate annual effective tax rate company adopt new guidance effective january impact company consolidate financial statement adoption january fasb issue new guidance intend clarify certain interaction accounting standard relate equity security equity method investment certain derivative guidance address accounting transition equity method accounting measure certain purchase option forward contract acquire investment company adopt new guidance effective january impact company consolidate financial statement adoption recently issue accounting standard adopt march fasb issue optional guidance ease potential burden account recognize effect reference rate reform financial reporting subsequently issue clarify amendment guidance provide optional expedient exception apply gaap contract hedge relationship transaction reference london interbank offer rate libor reference rate expect discontinue reference rate reform optional guidance effective issuance apply prospective basis time january december company currently evaluate impact adoption consolidate financial statement acquisition divestiture research collaboration license agreement company continue pursue acquisition establishment external alliance research collaboration license agreement complement internal research capability arrangement include upfront payment expense reimbursement payment party milestone royalty profit share arrangement contingent occurrence certain future event link success asset development company review market product pipeline examine candidate provide value outlicense portfolio assessment process divest certain asset pro forma financial information acquire business present historical financial result acquire entity significant compare company financial result transaction december merck acquire oncoimmune privately hold clinicalstage biopharmaceutical company upfront payment million addition oncoimmune shareholder eligible receive million future contingent regulatory approval milestone payment tiere royalty range oncoimmune lead therapeutic candidate know cdfc evaluate treatment patient hospitalize coronavirus disease covid transaction account acquisition asset agreement prior completion acquisition oncoimmune spunout certain right asset unrelated program new entity own exist shareholder oncoimmune connection closing acquisition merck invest million ownership interest new entity value million result million premium merck table content recognize net liability million company record research development expense million relate transaction december merck acquire velosbio inc velosbio privately hold clinicalstage biopharmaceutical company billion velosbio lead investigational candidate know vls antibodydrug conjugate target receptor tyrosine kinaselike orphan receptor ror currently evaluate treatment patient hematologic malignancy solid tumor transaction account acquisition asset merck record net asset million primarily cash research development expense billion relate transaction september merck seagen inc seagen know seattle genetics inc announce oncology collaboration globally develop commercialize seagens ladiratuzumab vedotin investigational antibodydrug conjugate target liv currently phase clinical trial breast cancer solid tumor collaboration pursue broad joint development program evaluate ladiratuzumab vedotin monotherapy combination keytruda pembrolizumab triplenegative breast cancer hormone receptorpositive breast cancer livexpresse solid tumor company equally share profit worldwide term agreement merck upfront payment million billion equity investment million share seagen common stock price share merck record million research development expense relate transaction reflect upfront payment million premium relate equity share base price seagen common stock closing date seagen eligible receive future contingent milestone payment billion include million development milestone billion salesbase milestone concurrent transaction seagen grant merck exclusive license commercialize tukysa tucatinib small molecule tyrosine kinase inhibitor treatment herpositive cancer asia middle east latin america region outside united states canada europe merck responsible marketing application seek approval territory support positive result herclimb clinical trial merck cofund portion tukysa global development plan encompass ongoing plan trial herpositive cancer include breast colorectal gastric cancer set forth global product development plan merck solely fund conduct countryspecific clinical trial necessary support anticipate regulatory application territory term agreement merck upfront payment aggregate million record research development expense seagen eligible receive future contingent regulatory approval milestone million receive tiere royalty range base annual sale level tukysa merck territory additionally september merck acquire biologic manufacturing facility locate dunboyne ireland takeda pharmaceutical company limit million million transaction account acquisition asset merck record property plant equipment million net asset million future contingent payment associate acquisition july merck acquire right sentinel flavor tabs sentinel spectrum chew virbac corporation million sentinel product provide protection common parasite dog transaction account acquisition asset merck recognize intangible asset million relate currently market product inventory million acquisition date estimate fair value identifiable intangible asset relate currently market product determine income approach actual cash flow likely different assumed intangible asset relate currently market product amortize estimate useful life year future contingent payment associate acquisition july merck ridgeback biotherapeutic ridgeback bio closely hold biotechnology company close collaboration agreement develop molnupiravir know eidd orally available antiviral candidate clinical development treatment patient covid merck gain exclusive worldwide right develop commercialize molnupiravir relate molecule term agreement ridgeback bio receive upfront payment eligible receive future contingent payment dependent achievement certain developmental regulatory approval milestone share net profit molnupiravir relate molecule approve merck table content ridgeback commit ensure medicine develop sarscov causative agent covid accessible affordable globally june merck acquire privately hold themis bioscience gmbh themis company focus vaccine include covid vaccine candidate immunemodulation therapie infectious disease cancer million acquisition originally provide merck additional contingent payment million transaction account acquisition business company determine fair value contingent consideration million acquisition date utilize probabilityweighte estimate cash flow stream appropriate discount rate dependent nature time milestone payment merck recognize intangible asset iprd million cash million defer tax asset million net liability million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach actual cash flow likely different assume january company announce discontinue development discuss result company record iprd impairment charge million research development expense company record reduction research development expense result decrease relate liability contingent consideration million future contingent milestone payment reduce million aggregate include million development milestone million regulatory approval milestone million commercial milestone merck international aids vaccine initiative inc iavi nonprofit scientific research organization dedicate address urgent unmet global health challenge announce collaboration develop investigational vaccine sarscov study prevention covid agreement provide upfront payment merck million provide future contingent payment base sale merck sign agreement biomedical advanced research development authority barda office assistant secretary preparedness response agency united states department health human service provide initial funding support merck effort january company announce discontinue development discuss january company announce discontinuation development program covid vaccine candidate follow merck review finding phase clinical study vaccine study generally tolerate immune response inferior see follow natural infection report sarscovcovid vaccine discontinuation company record charge million million reflect cost sale relate fixedasset material writeoff recognition liability purchase commitment remain million cost reflect research development expense represent amount relate themis acquisition note iprd impairment charge partially offset reduction relate liability contingent consideration january merck acquire arqule inc arqule publicly trade biopharmaceutical company focus kinase inhibitor discovery development treatment patient cancer disease total consideration pay billion include million sharebased compensation payment settle equity award attributable precombination service cash pay transaction cost behalf arqule company incur million transaction cost directly relate acquisition arqule consist entirely sharebased compensation payment settle nonveste equity award attributable postcombination service cost include sell general administrative expense arqule lead investigational candidate know arq novel oral bruton tyrosine kinase btk inhibitor currently evaluate treatment bcell malignancy transaction account acquisition business table content estimate fair value asset acquire liability assume arqule follow millions january cash cash equivalent iprd arq licensing arrangement arq defer income tax liability asset liability net total identifiable net asset goodwill consideration transfer estimate fair value identifiable intangible asset relate iprd determine income approach future net cash flow discount present value utilize discount rate actual cash flow likely different assumed goodwill allocate pharmaceutical segment deductible tax purpose transaction july merck acquire peloton therapeutics inc peloton clinicalstage biopharmaceutical company focus development novel small molecule therapeutic candidate target hypoxiainducible factor hif treatment patient cancer nononcology disease peloton lead candidate know novel investigational oral hif inhibitor latestage development renal cell carcinoma merck upfront payment billion additionally peloton shareholder eligible receive million regulatory approval million commercial sale united states billion salesbased milestone transaction account acquisition asset merck record cash million defer tax liability million net liability million acquisition date research development expense million relate transaction april merck acquire antelliq corporation antelliq leader digital animal identification traceability monitoring solution solution help veterinarian farmer pet owner gather critical datum improve management health wellbee livestock pet merck pay billion acquire outstanding share antelliq spend billion repay antelliqs debt transaction account acquisition business estimate fair value asset acquire liability assume antelliq follow million april cash cash equivalent account receivable inventory property plant equipment identifiable intangible asset useful life range year defer income tax liability asset liability net total identifiable net asset goodwill consideration transfer estimate fair value identifiable intangible asset relate primarily trade name determine income approach future net cash flow discount present value utilize discount rate actual cash flow likely different assumed goodwill recognize largely attributable anticipate synergy expect arise acquisition allocate animal health segment goodwill deductible tax purpose table content company result include month activity antelliq company result include month activity company incur million transaction cost directly relate acquisition antelliq consist largely advisory fee reflect sell general administrative expense april merck acquire immune design latestage immunotherapy company employ nextgeneration vivo approach enable bodys immune system fight disease million cash transaction account acquisition business merck recognize intangible asset million cash million net asset million excess consideration transfer fair value net asset acquire million record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach actual cash flow likely different assume transaction company record aggregate charge million cost sale conjunction termination collaboration agreement enter samsung bioepis ltd samsung insulin glargine charge reflect termination payment million represent reimbursement fee previously pay samsung merck agreement plus interest release merck ongoing obligation agreement charge include fix asset abandonment charge million inventory writeoff million relate cost million termination agreement impact company collaboration samsung june merck acquire viralytics limited viralytics australian publicly trade company focus oncolytic immunotherapy treatment range cancer aud million million transaction provide merck right know cva investigational oncolytic immunotherapy transaction account acquisition asset merck record net asset million primarily cash acquisition date research development expense million relate transaction future contingent payment associate acquisition march merck eisai ltd eisai enter strategic collaboration worldwide codevelopment cocommercialization lenvima orally available tyrosine kinase inhibitor discover eisai note remicadesimponi subsidiary scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company marketing right product europe russia turkey remicade lose market exclusivity major european market company long market exclusivity marketing territory company continue market exclusivity simponi marketing territory profit derive merck distribution product country equally divide merck companys marketing right respect product revert janssen pharmaceuticals inc second half collaborative arrangement merck enter collaborative arrangement provide company vary right develop produce market product collaborative partner party arrangement active participant expose significant risk reward dependent commercial success activity collaboration merck significant collaborative arrangement discuss astrazeneca july merck astrazeneca plc astrazeneca enter global strategic oncology collaboration codevelop cocommercialize astrazenecas lynparza olaparib multiple cancer type lynparza oral poly adpribose polymerase parp inhibitor currently approve certain type table content advance ovarian breast pancreatic prostate cancer company jointly develop commercialize lynparza monotherapy combination trial potential medicine independently merck astrazeneca develop commercialize lynparza combinations respective pdl medicine keytruda imfinzi company jointly develop commercialize astrazenecas koselugo selumetinib oral selective inhibitor mek mitogenactivate protein kinase mapk pathway multiple indication april koselugo approve food drug administration fda treatment pediatric patient year age old neurofibromatosis type symptomatic inoperable plexiform neurofibromas term agreement astrazeneca merck share development commercialization cost lynparza koselugo monotherapy nonpdlpd combination therapy opportunitie profit lynparza koselugo product sale generate monotherapie combination therapy share equally merck fund development commercialization cost keytruda combination lynparza koselugo astrazeneca fund development commercialization cost imfinzi combination lynparza koselugo astrazeneca principal lynparza koselugo sales transaction merck records share lynparza koselugo product sale net cost sale commercialization cost alliance revenue share development cost associate collaboration research development expense reimbursement receive astrazeneca research development expense recognize reduction research development cost agreement merck upfront payment astrazeneca billion payment million multiyear period certain license option million pay december million pay december million pay december upfront payment license option payment reflect research development expense addition agreement provide additional contingent payment merck astrazeneca relate successful achievement salesbase regulatory milestone merck determine probable sale lynparza future trigger million salesbase milestone payment merck astrazeneca accordingly merck record million liability correspond increase intangible asset relate lynparza prior merck accrue salesbase milestone payment aggregate billion relate lynparza million million million pay astrazeneca respectively potential future salesbase milestone payment billion accrue deem company probable time lynparza receive regulatory approval trigger capitalize milestone payment million million million respectively aggregate merck astrazeneca potential future regulatory milestone payment billion remain agreement intangible asset balance relate lynparza includes capitalize salesbased regulatory milestone payment billion december include intangible net amortize estimate useful life support project future cash flow subject impairment testing table content summarize financial information relate collaboration follow year end december alliance revenue lynparza alliance revenue koselugo total alliance revenue cost sale sell general administrative research development december receivables astrazeneca include current asset payable astrazeneca include accrued current liability represent amortization capitalize milestone payment include accrue milestone payment eisai march merck eisai ltd eisai announce strategic collaboration worldwide codevelopment cocommercialization lenvima lenvatinib orally available tyrosine kinase inhibitor discover eisai lenvima currently approve treatment certain type thyroid cancer hepatocellular carcinoma combination everolimus certain patient renal cell carcinoma combination keytruda treatment certain patient endometrial carcinoma agreement merck eisai develop commercialize lenvima jointly monotherapy combination keytruda eisai record lenvima product sale globally eisai principal lenvima sale transaction merck eisai share applicable profit equally merck record share lenvima product sale net cost sale commercialization cost alliance revenue expense incur development share company accordance collaboration agreement reflect research development expense certain expense incur solely merck eisai shareable collaboration agreement include cost incur excess agree cap cost relate certain combination study keytruda lenvima agreement merck upfront payment eisai million agree payment million certain option right million pay march million pay march million expect pay march company record aggregate charge billion research development expense relate upfront payment future option payment addition agreement provide additional contingent payment merck eisai relate successful achievement salesbase regulatory milestone merck determine probable sale lenvima future trigger salesbased milestone payment aggregate million merck eisai accordingly merck record liability million corresponding increase intangible asset relate lenvima prior merck accrue salesbase milestone payment aggregate million relate lenvima million million pay eisai respectively potential future salesbase milestone payment billion accrue deem company probable time lenvima receive regulatory approval trigger capitalize milestone payment million million respectively merck eisai potential future regulatory milestone payment million remain agreement intangible asset balance relate lenvima includes capitalize salesbased regulatory milestone payment billion december include intangible net amortize estimate useful life support project future cash flow subject impairment testing table content summarize financial information relate collaboration follow year end december alliance revenue lenvima cost sale sell general administrative research development december receivables eisai include current asset payable eisai include accrue current liability payable eisai include noncurrent liability represent amortization capitalize milestone payment include billion relate upfront payment option payment include accrue milestone future option payment include accrue milestone payment bayer company enter worldwide clinical development collaboration bayer bayer market develop soluble guanylate cyclase sgc modulator include bayer adempas riociguat approve treat pulmonary arterial hypertension chronic thromboembolic pulmonary hypertension company implement joint development commercialization strategy collaboration include clinical development bayer verquvo vericiguat approve fda january reduce risk cardiovascular death heart failure hospitalization follow hospitalization heart failure need outpatient intravenous diuretic adult verquvo review regulatory authority territory include japan agreement bayer commercialize adempas americas merck commercialize rest world verquvo merck commercialize united states bayer commercialize rest world company share development cost profit sale merck record sale adempas record sale verquvo marketing territory alliance revenue alliance revenue represent merck share profit sale bayer marketing territory product sale net cost sale commercialization cost addition agreement provide contingent payment merck bayer relate successful achievement salesbase milestone prior merck accrue million salesbase milestone payment collaboration million million pay bayer respectively follow fda approval verquvo note merck determine probable sale adempas verquvo future trigger remain million salesbase milestone payment accordingly merck record liability million corresponding increase intangible asset relate collaboration quarter intangible asset balance relate collaboration include acquire intangible asset balance capitalize salesbased milestone payment million december include intangible net amortize estimate useful life support project future cash flow subject impairment testing table content summarize financial information relate collaboration follow year end december alliance revenue adempas net sale adempas record merck total sale cost sale sell general administrative research development december receivables bayer include current asset payable bayer include noncurrent liability include amortization intangible asset represent accrue milestone payment restructure early merck approve new global restructuring program restructuring program worldwide initiative focus optimize company manufacture supply network reduce global real estate footprint program continuation company plant rationalization build prior restructure program include action associate plan spinoff organon company continue evaluate global footprint overall operating model subsequently identify additional action restructure program identify action time action currently contemplate restructure program expect substantially complete end cumulative pretax cost incur company implement program estimate approximately billion company estimate approximately cumulative pretax cost result cash outlay primarily relate employee separation expense facility shutdown cost approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest company expect record charge approximately million related restructuring program action previous global restructuring program substantially complete company record total pretax cost million million million related restructuring program activity inception restructuring program december merck record total pretax accumulate cost approximately billion segment report restructuring charge unallocated expense table content follow table summarize charge related restructuring program activity type cost separation accelerate cost depreciation total year end december cost sale sell general administrative research development restructuring cost year end december cost sale sell general administrative research development restructuring cost year end december cost sale sell general administrative research development restructuring cost separation cost associate actual headcount reduction headcount reduction probable reasonably estimate accelerated depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference depreciation expense recognize revise useful life asset base anticipate date site close divest equipment dispose depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future undiscounte cash flow sufficient recover respective book value merck recording accelerate depreciation revise useful life site asset anticipate site closure date particularly related manufacturing location continue adjust reflect change result regulatory factor activity include asset abandonment facility shutdown relate cost pretax gain loss result sale facility relate asset additionally activity include certain employeerelate cost associate pension postretirement benefit plan note sharebased compensation follow table summarize charge spend relate restructure program activity separation accelerate cost depreciation total restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december remain cash outlay expect substantially complete end table content financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause change foreign exchange rate objective revenue hedging program reduce variability cause change foreign exchange rate affect dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen chinese renminbi achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale forecast sale expect occur planning cycle typically year future company layer hedge time increase portion forecast sale hedge get close expect date forecast sale portion forecast sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument company manage anticipate transaction exposure principally purchase local currency option forward contract purchase collar option fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge unrealize gain loss contract record aoci reclassify sale hedge anticipate revenue recognize derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose company manage operating activity net asset position local subsidiary order mitigate effect exchange monetary asset liability company use balance sheet risk management program mitigate exposure net monetary asset denominate currency subsidiary functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument cash flow contract report operating activity consolidate statement cash flow monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year table content company use forward exchange contract hedge portion net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation unrealize gain loss contract record foreign currency translation adjustment oci remain aoci sale complete substantially complete liquidation subsidiary company exclude certain portion change fair value derivative instrument assessment hedge effectiveness exclude component change fair value exclude component recognize oci company recognize earning initial value exclude component straightline basis life derivative instrument marktomarket approach cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci effect company net investment hedge oci consolidated statement income show pretax gain loss recognize pretax gain loss recognize income expense net amount exclude comprehensive income effectiveness testing year end december net investment hedging relationship foreign exchange contract eurodenominate note amount reclassify aoci income relate sale subsidiary interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk february interest rate swap notional amount million mature swap effectively convert company billion fixedrate note variable rate debt december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table number interest rate total swap notional debt instrument par value debt swap hold note note note interest rate swap mature january interest rate swap contract designate hedge fair value change note attributable change benchmark libor swap rate fair value change note attributable change libor swap rate record interest expense offset fair value change swap contract cash flow contract report operating activity consolidate statement cash flow table content table present location amount record consolidated balance sheet relate cumulative basis adjustment fair value hedge december cumulative fair value hedge adjustment increase decrease include carrying hedge liability carry balance sheet line item hedge item include loan payable current portion longterm debt longterm debt present table fair value derivative gross basis segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative dollar derivative dollar balance sheet caption asset liability notional asset liability notional derivative designate hedge instrument interest rate swap contract current asset interest rate swap contract asset interest rate swap contract accrue current liability foreign exchange contract current asset foreign exchange contract asset foreign exchange contract accrue current liability foreign exchange contract noncurrent liability derivative designate hedge instrument foreign exchange contract current asset foreign exchange contract accrue current liability note company record derivative gross basis consolidated balance sheet company master netting agreement financial institution counterpartie concentration credit risk follow table provide information company derivative position subject master netting arrangement present net basis allow right offset counterparty cash collateral exchange master agreement relate credit support annexe december asset liability asset liability gross amount recognize consolidated balance sheet gross amount subject offset master netting arrangement offset consolidated balance sheet cash collateral postedreceive net amount table content table provide information location pretax gain loss derivative designate fair value cash flow hedge relationship sale income expense net comprehensive income loss year end december financial statement line item effect fair value cash flow hedge record gain loss fair value hedge relationship interest rate swap contract hedge item derivative designate hedge instrument impact cash flow hedging relationship foreign exchange contract loss gain recognize oci derivative decrease increase sale result aoci reclassification interest rate contract gain recognize income expense net derivative loss recognize oci derivative interest expense component income expense net table provide information income statement effect derivative designate hedge instrument derivative pretax gain loss recognize income year end december derivative designate hedge instrument income statement caption foreign exchange contract income expense net foreign exchange contract sale interest rate contract income expense net forward contract relate seagen common stock research development expense derivative contract mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate derivative contract serve economic hedge forecast transaction derivative serve economic hedge rise treasury rate december company estimate million pretax net unrealize loss derivative mature month hedge foreign currency denominate sale period reclassify aoci sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity table content investment debt equity security information investment debt equity security december follow gross unrealized gross unrealized amortize fair amortize fair cost gain loss value cost gain loss value government agency security foreign government bond commercial paper corporate note bond assetbacke security total debt security publicly trade equity security total debt publicly trade equity security unrealize net gain recognize income expense net equity security hold december million unrealize net gain recognize income expense net equity security hold december million december company million million respectively equity investment readily determinable fair value include asset company recognize unrealized gain million million respectively income expense net certain equity investment base favorable observable price change transaction involve similar investment investee addition company recognize unrealized loss million million respectively income expense net relate certain investment base unfavorable observable price change cumulative unrealized gain cumulative unrealized loss base observable price change investment equity investment readily determinable fair value million million respectively fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset liability value determine pricing model discount cash flow methodology similar technique significant unobservable input asset liabilitie determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement level level level total level level level total asset investment foreign government bond commercial paper corporate note bond assetbacke security government agency security publicly trade equity security asset government agency security publicly trade equity security derivative asset forward exchange contract interest rate swap purchase currency option total asset liability liabilitie contingent consideration derivative liability forward exchange contract write currency option interest rate swap total liability investment include asset restrict use include payment benefit employee benefit plan fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant december cash cash equivalent include billion billion respectively cash equivalent consider level fair value hierarchy table content contingent consideration summarize information change liabilitie contingent consideration associate business acquisition follow fair value january addition change estimate fair value payment fair value december record cost sale research development expense income expense net include cumulative translation adjustment balance december include million record current liability amount expect pay month december million million respectively liability relate termination sanofi pasteur msd joint venture termination merck record liability contingent future royalty payment net sale merck product previously sell joint venture december fair value liability determine utilize estimate time project cash flow riskadjuste discount rate present value cash flow addition contingent consideration relate acquisition themis change estimate fair value liability contingent consideration largely attributable increase liability record connection termination sanofi pasteur msd spmsd joint venture increase partially offset decline relate discontinuation covid vaccine program obtain acquisition themis payment contingent consideration year relate spmsd liability describe fair value measurement company financial instrument cash cash equivalent receivables payable reflect balance sheet carrying value approximate fair value shortterm nature estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate recent observable market price consider level fair value hierarchy concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline majority company account receivable arise product sale united states europe china primarily drug wholesaler retailer hospital government agency manage health care provider pharmacy benefit manager company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor global economic condition include volatility associate international sovereign economy associate impact financial market business company customer large account receivable balance mckesson corporation amerisourcebergen corporation cardinal health inc represent aggregate approximately total account receivable december company monitors creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale company account receivable factoring agreement financial institution certain country sell account receivable company factor billion billion account receivable fourth quarter respectively factor arrangement reduce outstanding account receivable cash receive financial institution report operating activity table content consolidated statement cash flow certain factoring arrangement ease administration company collect customer payment relate factored receivables remit financial institution december company collect million million respectively behalf financial institution reflect restrict cash current asset relate obligation remit cash accrue current liability company remit cash financial institution january respectively net cash flow relate collection report financing activity consolidate statement cash flow cost factoring account receivable minimis derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty cash collateral advanced company counterpartie million december cash collateral receive company counterpartie million december obligation return collateral record accrue current liability inventory inventory december consist finished good raw material work process supply total approximate current cost decrease lifo cost recognize inventory asset inventory value lifo method comprise approximately billion billion december respectively amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year addition amount include million million december respectively inventory produce preparation product launch goodwill intangible follow table summarize goodwill activity segment pharmaceutical animal health total balance january acquisition impairment balance december acquisition divestiture balance december include cumulative translation adjustment goodwill balance certain adjustment accumulate goodwill impairment losse million december table content addition goodwill pharmaceutical segment primarily relate acquisition arqule themis note addition goodwill animal health segment primarily relate acquisition antelliq note impairment goodwill nonreportable segment relate certain business healthcare service segment healthcare service segment fully divest quarter intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right license iprd trade name acquire intangible include product product right license trade name patent initially record fair value assign estimate useful life amortize primarily straightline basis estimate useful life company significant acquire intangible net basis relate human health market product include product product right december include zerbaxa million implanonnexplanon million gardasilgardasil million dificid million bridion million sivextro million simponi million additionally company billion net acquire intangible related animal health market product december billion relate primarily trade name obtain acquisition antelliq note company significant net intangible asset include license december include lynparza billion lenvima billion result collaboration astrazeneca eisai note december iprd primarily relate obtain acquisition arqule note gefapixant obtain acquisition afferent pharmaceutical company intangible asset relate collaboration bayer note carry value million december reflect table company record impairment charge billion cost sale relate zerbaxa injection combination antibacterial betalactamase inhibitor treatment certain bacterial infection december company temporarily suspend sale zerbaxa subsequently issue product recall follow identification product sterility issue recall constitute trigger event require evaluation zerbaxa intangible asset impairment company revise cash flow forecast zerbaxa utilize certain assumption return market timeline anticipate uptake sale revise cash flow forecast indicate zerbaxa intangible asset value fully recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate zerbaxa compare related carrying value result impairment charge note company wroteoff inventory million cost sale relate zerbaxa recall remain intangible asset balance relate zerbaxa million december company record impairment charge relate market product intangible million million relate sivextro product treatment acute bacterial skin skin structure infection cause designate susceptible grampositive organism reorganization reprioritization internal sale force company decision cease promotion sivextro market end decision result reduce cash flow projection sivextro indicate sivextro intangible asset value fully recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate sivextro compare related carrying value result impairment charge note table content iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize iprd account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project company separate determination useful life asset begin amortization company record million iprd impairment charge research development expense relate decision discontinue development program covid vaccine candidate follow merck review finding phase clinical study vaccine study generally tolerate immune response inferior see follow natural infection report sarscovcovid vaccines discontinuation development program result reversal relate liability contingent consideration million note company record million iprd impairment charge million relate writeoff intangible asset balance program obtain connection acquisition iomet pharma ltd follow review clinical trial result conduct merck external clinical trial result similar compound discontinuation clinical development program result reversal relate liability contingent consideration million company record million iprd impairment charge million relate writeoff remain intangible asset balance program obtain connection smartcell acquisition follow decision terminate program product development issue discontinuation clinical development program result reversal relate liability contingent consideration million iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate company recognize additional noncash impairment charge future relate market product pipeline program charge material aggregate amortization expense primarily record cost sale billion billion billion estimate aggregate amortization expense year follow billion billion billion billion billion loan payable longterm debt lease loan payable loan payable december include billion note billion commercial paper million longdate note subject repayment option holder loan payable december include billion note billion commercial paper million longdate note subject repayment option holder weightedaverage interest rate commercial paper borrowing year end december respectively table content longterm debt longterm debt december consist note note note note note note note note eurodenominate note note note note note note note note eurodenominate note eurodenominate note eurodenominate note note note note debenture note debenture debenture note eurodenominate note present table include million million december respectively borrowing variable rate result effective interest rate respectively exception debenture note list table redeemable merck option time vary redemption price june company issue billion principal senior unsecured note consist billion note billion note billion note billion note merck net proceed offer general corporate purpose include limitation repayment outstanding commercial paper borrowing indebtedness upcoming maturity effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date certain company borrowing require merck comply covenant december company compliance covenant table content aggregate maturity longterm debt year follow billion billion billion billion billion company billion credit facility mature june facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility lease company operating lease primarily manufacture facility research development facility corporate office employee housing vehicle certain equipment company determine arrangement lease inception evaluate contract embed lease company exercise judgment determine explicit implicit identify asset contract merck control use asset embed lease primarily associate contract manufacturing organization immaterial lease term include option extend terminate lease reasonably certain merck exercise option real estate lease facility average remain lease term year include option extend lease year applicable vehicle lease generally effect year company record shortterm lease lease initial term month balance sheet merck currently shortterm lease lease expense operating lease payment recognize straightline basis term lease operating lease asset liability recognize base present value lease payment lease term company lease readily determinable implicit discount rate company use incremental borrowing rate calculate present value lease payment asset class quarterly basis update incremental borrowing rate determine base average remain lease term asset class company pretax cost debt term update rate asset class apply prospectively new lease company separate lease component payment rent real estate taxis insurance cost nonlease component commonarea maintenance cost event agreement contain merck include lease nonlease component purpose calculate rightofuse asset relate lease liability nonlease component fix vehicle lease employee housing company apply portfolio approach effectively account operating lease asset liability certain company lease agreement contain variable lease payment adjust periodically inflation actual operating expense true up compare estimate amount amount immaterial sublease income activity relate sale leaseback transaction immaterial merck lease agreement contain material residual value guarantee material restrictive covenant operate lease cost million million rental expense operating lease net sublease income million cash pay amount include measurement operating lease liability million million operating lease asset obtain exchange lease obligation million million supplemental balance sheet information relate operating lease follow december asset asset liability accrue current liability noncurrent liability weightedaverage remain lease term year weightedaverage discount rate include prepaid lease relate lease liability table content maturity operating lease liability follow total lease payment imputed interest december company enter additional real estate operating lease commence obligation associate lease total million contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include governmental environmental matter opinion company unlikely resolution matter material company financial condition result operation cash flow give nature litigation discuss complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation settlement posture party litigation factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance product liability product liability litigation fosamax previously disclose merck defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case pende merck federal state court plaintiff vast majority case generally allege sustained femur fracture andor bone injury femur fracture association use fosamax federal case involve allegation femur fracture transfer multidistrict litigation district new jersey femur fracture mdl bellwether case try date femur fracture mdl glynn merck jury return verdict merck favor addition june femur fracture mdl court grant merck motion judgment matter law glynn case hold plaintiff failure warn claim preempt federal law table content august femur fracture mdl court enter order require plaintiff femur fracture mdl cause case assert claim femur fracture injury take place prior september dismiss base court preemption decision glynn case pursuant cause order march femur fracture mdl court dismiss prejudice approximately case preemption ground plaintiff approximately case appeal decision court appeal circuit circuit march circuit issue decision reverse femur fracture mdl court preemption ruling remand appeal case femur fracture mdl court supreme court decide circuit incorrectly conclude issue preemption resolve jury accordingly vacate judgment circuit remand proceeding circuit address issue manner consistent supreme courts opinion november circuit remand case district court order allow court determine instance plaintiff state law claim preempt federal law standard describe supreme court opinion briefing issue close party await decision district court accordingly december approximately case actively pende femur fracture mdl december approximately case allege femur fracture file new jersey state court pending judge james hyland middlesex county party select initial group case review fact discovery merck continue select additional case review december approximately case allege femur fracture file pende california state court femur fracture case file california state court coordinate single judge orange county california additionally femur fracture case pende state court discovery presently stay femur fracture mdl state court california merck intend defend lawsuit januviajanumet previously disclose merck defendant product liability lawsuit unite states involve januvia andor janumet december merck aware approximately product user allege januvia andor janumet cause development pancreatic cancer injury claim file multidistrict litigation district court southern district california mdl outside mdl majority claim file coordinated proceeding superior court california county los angeles california state court november mdl california state court separate opinion grant summary judgment defendant ground federal preemption plaintiff appeal forum november court appeals ninth circuit vacate judgment remand discovery november california state appellate court reverse remand similar ground march party mdl california coordinate proceeding agree coordinate adopt schedule completing discovery general causation preemption issue renew summary judgment expert motion briefing motion complete hearing mdl california state court judge take place october december respectively december product user claim pende merck state court california include illinois june illinois trial court deny merck motion summary judgment base federal preemption merck appeal illinois appellate court affirm december merck file petition leave appeal illinois supreme court february april illinois supreme court stay consideration pende petition appeal supreme court issue opinion merck sharp dohme corp albrecht relate fosamax matter discuss merck file table content opinion albrecht illinois supreme court june petition leave appeal decide september illinois supreme court direct intermediate appellate court reconsider early rule illinois appellate court issue favorable decision conclude consistent albrecht preemption present legal question resolve court illinois appellate court issue mandate state trial court december schedule case management conference addition claim note company agree toll statute limitation approximately additional claim company intend continue defend lawsuit vioxx merck reach settlement attorney general utah fully resolve state previously disclose civil lawsuit allege merck misrepresented safety vioxx resolution merck pay state million settlement constitute admission merck liability wrongdoing agreement mark final resolution litigation involve vioxx united states ongoing vioxx litigation certain country outside united states governmental proceeding previously disclose fall company receive record subpoena attorney office district vermont usao pursuant section health insurance portability accountability act hipaa relate investigation potential health care offense subpoena seek information relate actual potential business relationship arrangement merck practice fusion inc pfi cloudbase electronic health record ehr company acquire allscripts january company cooperate government respond subpoena subsequently merck receive second record subpoena usao broaden government information request seek information relate merck relationship ehr company shortly usao serve civil investigation demand cid merck similarly seek information company relationship ehr vendor cid explain government conduct false claim act investigation concern merck andor pfi submit claim federal health care program violate federal antikickback statute merck cooperate government investigation previously disclose april merck receive set investigative interrogatory california attorney general office pursuant investigation conduct agreement allegedly affect delay competition lantus insulin market interrogatory seek information concern merck development insulin glargine product subsequent termination merck patent litigation sanofi concern lantus resolution litigation merck cooperate california attorney general investigation previously disclose june merck receive cid department justice cid request answer interrogatory document temperature excursion thirdparty storage facility contain certain merck product merck cooperate government investigation intend produce information andor document necessary response cid previously disclose company subsidiary china receive continue receive inquiry operation chinese governmental agency inquiry relate matter involve multinational pharmaceutical company chinese entity business company company policy cooperate authority provide response appropriate previously disclose time time company receive inquiry subject preliminary investigation activity competition governmental authority market outside united states authority include regulator administrative authority law enforcement similar official preliminary investigation activity include site visit formal informal request demand document material inquiry interview similar matter certain preliminary inquiry activity lead commencement formal proceeding proceeding determine adversely company monetary fine andor remedial undertaking require table content commercial litigation zetia antitrust litigation previously disclose merck msd schering corporation msp singapore company llc collectively merck defendant defendant putative class action optout lawsuit file behalf direct indirect purchaser zetia allege violation federal state antitrust law state statutory common law cause action case consolidated pretrial purpose federal multidistrict litigation judge rebecca beach smith eastern district virginia december court deny merck defendant motion dismiss stay direct purchaser putative class action pende bilateral arbitration august district court adopt report recommendation magistrate judge respect merck defendant motion dismiss nonarbitration issue grant deny merck defendant motion dismiss addition june representative putative direct purchaser class file amend complaint august retailer optout plaintiff file amend complaint december district court grant merck defendant motion dismiss extent motion seek dismissal claim overcharge pay entity purchase generic ezetimibe par pharmaceutical inc par pharmaceutical dismiss claim overcharge november direct purchaser plaintiff indirect purchaser plaintiff file motion class certification august district court grant direct purchaser motion class certification certify class direct purchaser november court appeal fourth circuit grant merck defendant motion permission appeal district court order august magistrate judge recommend court grant motion class certification file putative indirect purchaser class merck defendant object report recommendation await decision district court august merck defendant file motion summary judgment motion plaintiff file motion partial summary judgment motion motion fully brief court likely hold hear compete motion trial matter adjourn september united healthcare services inc file lawsuit united states district court district minnesota merck uhc action uhc action make similar allegation zetia class action september united states judicial panel multidistrict litigation transfer case eastern district virginia proceed multidistrict zetia litigation progress december humana inc file lawsuit superior court state california county san francisco merck allege defendant violate state antitrust law multiple state december centene corporation file lawsuit superior court state california county san francisco defendant humana lawsuit allege similar anticompetitive act allege zetia class action rotavirus vaccine antitrust litigation previously disclose msd defendant putative class action lawsuit file behalf direct purchaser rotateq allege violation federal antitrust law case consolidate eastern district pennsylvania january court deny msds motion compel arbitration dismiss consolidate complaint february msd appeal court order arbitration circuit october circuit vacate district court order remand limited discovery issue arbitrability july msd file renew motion compel arbitration plaintiff file cross motion summary judgment arbitrability november district court deny msds motion grant plaintiff motion december msd file notice appeal circuit bravecto litigation previously disclose january company serve complaint united states district court district new jersey seeking certify nationwide class action purchaser user bravecto fluralaner product united states territory december complaint contend bravecto cause neurological event allege violation new jersey consumer table content fraud act breach warranty product liability relate theory similar case file quebec canada qui tam litigation previously disclose june district court eastern district pennsylvania unseal complaint file company federal false claim act employee allege thing company defraud government falsify datum connection clinical study conduct mump component company mmr vaccine complaint allege fraud take place government right participate prosecution lawsuit notify court decline exercise right employee pursue lawsuit involvement government addition previously disclose putative class action lawsuit behalf direct purchaser mmr vaccine charge company misrepresent efficacy mmr vaccine violation federal antitrust law state consumer protection law pende eastern district pennsylvania september court deny merck motion dismiss false claim act suit grant deny motion dismiss thenpende antitrust suit result false claim act suit antitrust suit proceed discovery complete party file brief cross motion summary judgment currently pende court company continue defend lawsuit merck kgaa litigation previously disclose january protect longestablished brand rights united states company file lawsuit merck kgaa darmstadt germany kgaa historically operate emd group united states allege improperly use merck united states kgaa file suit company france germany switzerland mexico india australia singapore hong kong china allege thing unfair competition trademark infringement andor corporate infringement australia singapore hong kong india kgaa allege breach party coexistence agreement litigation ongoing united states trial date set ongoing numerous jurisdiction outside united states company defend suit jurisdiction patent litigation time time generic manufacturers pharmaceutical product file abbreviate new drug application nda fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten period exclusivity product respect product acquire acquisition potentially significant intangible asset impairment charge bridion january november company receive multiple paragraph certification letter hatchwaxman act notify company generic drug company file application fda seek prepatent expiry approval sell generic version bridion sugammadex injection march april december company file patent infringement lawsuit district court district new jersey northern district west virginia generic company action district new jersey consolidated lawsuit assert patent cover sugammadex method sugammadex automatically stay fda approval generic application june adverse court decision whichever occur early mylan pharmaceuticals inc mylan api llc mylan inc mylan file motion dismiss district new jersey lack venue failure state claim certain defendant northern district west virginia failure state claim certain defendant new jersey motion decide west virginia action stay pende resolution new jersey motion table content januvia janumet janumet fda grant pediatric exclusivity respect januvia janumet janumet provide month exclusivity united states expiration patent list fdas orange book include exclusivity key patent protection extend january company anticipate sale januvia janumet united states decline significantly loss market exclusivity januvia janumet janumet contain sitagliptin phosphate monohydrate company patent cover certain phosphate salt polymorphic form sitagliptin determine valid preclude generic manufacturer make sitagliptin phosphate salt polymorphic form patent inclusive pediatric exclusivity expire saltpolymorph patent par pharmaceutical file suit company district court district new jersey seek declaratory judgment invalidity saltpolymorph patent response company file patent infringement lawsuit district court district delaware par pharmaceutical additional company indicate intent market generic version januvia janumet janumet follow expiration key patent protection prior expiration saltpolymorph patent later grant patent own company cover janumet formulation inclusive pediatric exclusivity expire company file patent infringement lawsuit mylan northern district west virginia judicial panel multidistrict litigation enter order transfer company lawsuit mylan district court district delaware coordinate consolidated pretrial proceeding case pende district district court district delaware schedule lawsuit single threeday trial invalidity issue october court schedule separate oneday trial infringement issue november january extent trial necessary company case mylan district court northern district west virginia conditionally schedule threeday trial december issue company settle generic company provide generic company bring product market early certain circumstance additionally mylan file petition inter parte review ipr united states patent trademark office uspto seek invalidity claim saltpolymorph patent manufacturer join uspto institute ipr proceeding find reasonable likelihood challenge claim valid trial hold february final decision expect challenge successful unchallenged claim saltpolymorph patent remain valid subject court proceeding describe germany generic company seek revocation supplementary protection certificate spc janumet generic company successful janumet lose market exclusivity germany early july challenge janumet spc occur portugal finland occur european country nexplanon june microspherix llc microspherix sue company district court district new jersey assert manufacturing use sale importation nexplanon infringe microspherixs patent claim radioopaque implantable drug delivery device microspherix claim damage september patent expire company bring ipr proceeding uspto successfully stay district court action uspto invalidate claim assert company company appeal decision find claim valid court appeal federal circuit affirm usptos decision matter long stay district court company currently litigate invalidity noninfringement remain asserted claim litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion company likelihood loss remote reasonably possible loss associate resolution proceeding expect material company financial condition result operation cash flow individually aggregate table content legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate environmental matter company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial condition result operation liquidity company company take active role identify accrue cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party management opinion liability environmental matter probable reasonably estimable accrue total million december liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed approximately million aggregate management believe expenditure result material adverse effect company financial condition result operation liquidity year table content equity merck certificate incorporation authorize share common stock share prefer stock capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january purchase treasury stock issuance balance december issuance primarily reflect activity sharebase compensation plan company enter accelerated share repurchase asr agreement thirdparty financial institution dealer asr agreement merck agree purchase billion merck common stock total initial delivery million share merck common stock base thencurrent market price dealer merck payment billion merck dealer fund exist cash investment shortterm borrowing settlement asr agreement merck receive additional million share determine average daily volume weightedaverage price merck common stock term asr program negotiate discount bring total share receive merck program million sharebase compensation plan company sharebase compensation plan company grant restrict stock unit rsus performance share unit psus certain management level employee addition employee nonemployee director grant option purchase share company common stock fair market value time grant plan approve company shareholder december million share collectively authorize future grant company sharebase compensation plan award settle treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus psus dividend declare vest period payable employee vest psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period subject term applicable award psu award generally vest year rsu award generally vest onethird year threeyear period total pretax sharebase compensation cost record million million million respectively relate income tax benefit million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield risk table content free interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree interest rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term year value outstanding january grant exercise forfeit outstanding december exercisable december additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited nonveste december december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expense table content pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary addition company provide medical benefit principally eligible retiree dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost credit pension postretirement benefit plan consist follow component pension benefit international postretirement benefit year end december service cost interest cost expect return plan asset amortization unrecognize prior service cost net loss gain amortization termination benefit curtailment settlement net periodic benefit cost credit change net periodic benefit cost year year pension plan largely attributable change discount rate affect net loss amortization connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment record pension postretirement benefit plan settlement record certain international pension plan reflect table component net periodic benefit cost credit service cost component include income expense net note exception certain amount termination benefit curtailment settlement record restructuring cost event give rise termination benefit curtailment settlement related restructuring action note table content obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow pension benefit postretirement international benefit fair value plan asset january actual return plan asset company contribution effect exchange rate change benefit pay settlement fair value plan asset december benefit obligation january service cost interest cost actuarial loss gain benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement benefit obligation december fund status december recognize asset accrue current liability noncurrent liability actuarial loss gain primarily reflect change discount rate december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan table content information relate fund status select pension plan december follow international pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately company pension investment categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow fair value measurement fair value measurement level level level nav total level level level nav total pension plan cash cash equivalent investment fund develop market equities emerge market equity mortgage assetbacked security government agency obligation equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security investment plan asset fair value international pension plan cash cash equivalent investment fund develop market equity government agency obligation emerge market equities corporate obligation fix income obligation real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy nav amount present table intend permit reconciliation fair value hierarchy fair value plan asset december plans level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance real insurance real contract estate total contract estate total pension plan balance january actual return plan asset relate asset hold december relate asset sell year purchase sale net balance december international pension plan balance january actual return plan asset relate asset hold december purchase sale net transfer level balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement level level level nav total level level level nav total cash cash equivalent investment fund develop market equities emerge market equity government agency obligation mortgage assetbacke security equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security plan asset fair value certain investment measure net asset value nav share equivalent classify fair value hierarchy nav amount present table intend permit reconciliation fair value hierarchy fair value plan asset december company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plans benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan table content target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline expect contribution expect contribution approximately million pension plan approximately million international pension plan approximately million postretirement benefit plan expect benefit payment expect benefit payment follow international pension postretirement pension benefit benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income net loss amount reflect difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net periodic benefit cost average remain service life employee follow amount reflect component oci pension plan postretirement international benefit plan year end december net loss gain arise period prior service cost credit arise period net loss gain amortization include benefit cost prior service credit amortization include benefit cost table content actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension postretirement benefit plan international pension plan information follow pension postretirement benefit plan international pension plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate interest credit rate benefit obligation discount rate salary growth rate interest credit rate pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determine plan basis expect rate return plan develop consider longterm historical return data current market condition actual return plan asset reference information longterm return expectation asset category weightedaverage expect return plan target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate expect rate return company pension postretirement benefit plan range compare range health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate saving plan company maintain define contribution saving plan united states company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net income expense net consist year end december interest income interest expense exchange loss income investment equity security net net periodic define benefit plan credit cost service cost net include net realize unrealized gain loss investment equity security own directly ownership interest investment fund unrealize gain loss investment directly own determined end report period ownership interest investment fund account quarter lag net present table include million goodwill impairment charge relate certain business healthcare service segment note net include gain million relate settlement certain patent litigation income million relate astrazenecas option exercise connection termination company relationship astrazeneca azlp gain million result receipt milestone payment outlicense migraine clinical development program net include million goodwill impairment charge relate certain business healthcare service segment note million charge relate writedown asset hold sale fair value anticipation dissolution company joint venture supera farma laboratorio brazil interest pay million million million taxis income reconciliation effective tax rate statutory rate follow tax rate tax rate tax rate statutory rate apply income taxis differential arise foreign earning gilti foreignderive intangible income deduction tax credit tax settlement acquisition velosbio restructuring acquisition oncoimmune state taxis acquisitionrelate cost include amortization valuation allowance acquisition peloton tax cut job act table content tax cut job act tcja enact december company reflect impact tcja financial statement application certain provision tcja remain subject interpretation certain instance company reasonable estimate effect tcja finalize result additional income tax expense company remain transition tax liability tcja reduce payment utilization foreign tax credit billion december million include income taxis payable remainder billion include noncurrent liability result transition tax tcja company long indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign withholding taxis apply company remain indefinitely reinveste respect financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable foreign earning tax rate differential tax rate reconciliation primarily reflect impact operation jurisdiction different tax rate united states particularly ireland switzerland singapore puerto rico operate tax incentive grant begin expire yield favorable impact effective tax rate compare statutory rate end new reduce tax rate arrangement agree switzerland certain newly active legal entity income taxis consist year end december domestic foreign taxis income consist year end december current provision federal foreign state defer provision federal foreign state table content defer income taxis december consist asset liability asset liability product intangible license inventory relate accelerated depreciation equity investment pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize asset defer income taxis company net operating loss nol carryforward jurisdiction december million defer taxis nol carryforward relate foreign jurisdiction valuation allowance million establish foreign nol carryforward foreign defer tax asset addition company million defer tax asset relate tax credit carryforward nol carryforward expect fully utilize prior expiry income taxis pay billion billion billion respectively tax benefit relate stock option exercise million million million reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitation balance december amount reflect settlement irs discuss include million relate divestiture merck consumer care business company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion table content company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease approximately million month result audit closure settlement expiration statute limitation ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact time reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure interest penalty associate uncertain tax position amount expense benefit million million million amount reflect beneficial impact tax settlement include settlement discuss liability accrue interest penalty million million december respectively internal revenue service irs conclude examination merck federal income tax return result company require payment million company reserve unrecognize tax benefit year examination exceed adjustment relate examination period company record million net tax benefit net benefit reflect reduction reserve unrecognize tax benefit tax position relate year examination partially offset additional reserve tax position previously reserve irs currently conduct examination company tax return year addition state foreign tax examination progress jurisdiction company income tax return open examination period earning share calculation earning share share millions follow year end december net income attributable merck inc average common share outstanding common share issuable average common share outstanding assume dilution basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive table content comprehensive income loss change aoci component follow employee cumulative accumulate benefit translation comprehensive derivative investment plan adjustment income loss balance january net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis adoption asu adoption asu balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis relate foreign currency cash flow hedge reclassify aoci sale represent net realize gain loss sale availableforsale investment reclassify aoci income expense net include net amortization prior service cost actuarial gain loss include net periodic benefit cost note include pension plan net loss billion billion december respectively postretirement benefit plan net gain million million december respectively pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december respectively table content segment reporting company operation principally manage product basis include operate segment pharmaceutical animal health segment reportable segment pharmaceutical segment include human health pharmaceutical vaccine product human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sale center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile animal health segment discover develop manufacture market wide range veterinary pharmaceutical vaccine product health management solution service prevention treatment control disease major livestock companion animal specie company offer extensive suite digitally connect identification traceability monitoring product company sell product veterinarian distributor animal producer company previously healthcare service segment provide service solution focus engagement health analytic clinical service improve value care deliver patient company divest remain business segment quarter company previously alliance segment primarily include activity company relationship astrazeneca relate sale nexium prilosec conclude table content sale company product follow year end december intl total intl total intl total pharmaceutical oncology keytruda alliance revenue lynparza alliance revenue lenvima emend vaccines gardasilgardasil proquadmmr iivarivax pneumovax rotateq vaqta hospital acute care bridion noxafil prevymis primaxin cancidas invanz cubicin zerbaxa immunology simponi remicade neuroscience belsomra virology isentressisentress zepatier cardiovascular zetia vytorin atozet alliance revenue adempas adempas diabete januvia janumet womens health implanonnexplanon nuvare diversify brand singulair cozaarhyzaar arcoxia nasonex follistim pharmaceutical total pharmaceutical segment sale animal health livestock companion animal total animal health segment sale segment sale total segment sale plus international equal total round alliance revenue represent merck share profit product sale net cost sale commercialization cost note alliance revenue represent merck share profit sale bayer marketing territory product sale net cost sale commercialization cost note pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent sale nonreportable segment healthcare service fully divest quarter alliance conclude primarily comprise miscellaneous corporate revenue include revenue hedging activity thirdparty manufacture sale table content consolidated sale geographic area derive follow year end december united states europe middle east africa china japan asia pacific china japan latin america reconciliation segment profit income taxis follow year end december segment profit pharmaceutical segment animal health segment segment total segment profit profit unallocate interest income interest expense depreciation amortization research development amortization purchase accounting adjustment restructure cost charge relate termination collaboration samsung unallocated net income taxis pharmaceutical segment profit comprise segment sale standard cost sell general administrative expense directly incur segment animal health segment profit comprise segment sale cost sale sell general administrative expense research development cost directly incur segment internal management reporting present chief operating decision maker merck allocate remain cost sale include segment profit describe research development expense incur merck research laboratory companys research development division focus human healthrelated activity general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit addition cost related restructuring activity amortization purchase accounting adjustment allocate segment profit primarily comprise miscellaneous corporate profit operate profit relate thirdparty manufacturing sale unallocate net include expense corporate manufacturing cost center goodwill intangible asset impairment charge gain loss sale business expense income relate change estimate fair value liability contingent consideration miscellaneous income expense item table content equity income loss affiliate depreciation amortization include segment profit follow pharmaceutical animal health total year end december include segment profit equity income loss affiliate depreciation amortization year end december include segment profit equity income loss affiliate depreciation amortization year end december include segment profit equity income loss affiliate depreciation amortization property plant equipment net geographic area locate follow december united states europe middle east africa asia pacific china japan latin america china japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director stockholders merck inc opinion financial statement internal control financial reporting audit accompany consolidated balance sheet merck inc subsidiary company december relate consolidated statement income comprehensive income equity cash flow year period end december include related note collectively refer consolidated financial statement audit company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion consolidated financial statement refer present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso basis opinion company management responsible consolidated financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report internal control financial reporting appear item responsibility express opinion company consolidate financial statement companys internal control financial reporting base audits public accounting firm register public company accounting oversight board united states pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audits obtain reasonable assurance consolidated financial statement free material misstatement error fraud effective internal control financial reporting maintain material respect audits consolidated financial statement include perform procedure assess risk material misstatement consolidated financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure consolidated financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation consolidate financial statement audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement table content inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate critical audit matter critical audit matter communicate matter arise current period audit consolidated financial statement communicate require communicate audit committee relate account disclosure material consolidated financial statement involve especially challenge subjective complex judgment communication critical audit matter alter way opinion consolidated financial statement take communicate critical audit matter provide separate opinion critical audit matter account disclosure relate customer discount accrual medicaid manage care medicare rebate describe note consolidated financial statement company record certain variable consideration include discount estimate time sale generally expect value method amount accrue aggregate customer discount december billion evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager federal state agency customer amount accrue certain discount form rebate amount owe base definitive contractual agreement legal requirement private sector manage care public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision rebate base expect patient usage inventory level distribution channel determine contractual obligation benefit provider management use historical customer segment utilization mix sale forecast change product mix price inventory level distribution channel government pricing calculation prior payment history order estimate expect provision principal consideration determination perform procedure relate customer discount accrual medicaid manage care medicare rebate critical audit matter significant judgment management significant measurement uncertainty involve develop provision provision include assumption relate change price historical customer segment utilization mix pertain forecast customer claim fully pay subsequent period turn lead high degree auditor judgment subjectivity effort apply procedure relate assumption evaluate evidence obtain procedure address matter involve perform procedure evaluate audit evidence connection form overall opinion consolidated financial statement procedure include testing effectiveness control relate customer discount accrual medicaid manage care medicare rebate include management control assumption estimate correspond rebate accrual procedure include develop independent estimate rebate accrual utilize party datum historical customer segment utilization mix change price term specific rebate program historical trend actual rebate claim pay compare independent estimate rebate accrual record management iii testing actual rebate claim pay include evaluate claim consistency contractual term company rebate agreement pricewaterhousecooper llp florham park new jersey february serve company auditor table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend act effective fourth quarter change internal control financial reporting materially affect reasonably likely materially affect company internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice annually employee company require complete code conduct training training reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate table content framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear kenneth frazier robert davis chairman president executive vice president global services chief executive officer chief financial officer item information table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion proposal election director company proxy statement annual meeting shareholder hold information executive officer set forth document require information compliance section securities exchange act applicable incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold company code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer controller code conduct available company website wwwmerckcomcompany overviewcultureandvaluescodeofconductvaluesandstandards company intend disclose future amendment certain provision code conduct waivers code conduct grant executive officer director website business day follow date amendment waiver merck employee responsible adhering business practice accordance law ethical principle reflect high standard corporate individual behavior require information identification audit committee audit committee financial expert incorporate reference discussion head board meeting committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity award table option exercise stock vest table pension benefit table nonqualifie defer compensation table potential payment termination change control include discussion subheading separation change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate schedule director fee table director compensation table company proxy statement annual meeting shareholder hold require information heading compensation benefit committee interlock insider participation compensation benefit committee report incorporate reference company proxy statement annual meeting shareholder hold table content item security ownership certain beneficial owner management relate stockholder matter information respect security ownership certain beneficial owner management incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualify plan merck saving plan number number security remain security available future issue weightedaverage issuance equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck inc incentive stock plan merck inc nonemployee directors stock option plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan exclude share phantom stock defer msd employee deferral program share phantom stock defer merck inc plan defer payment director compensation item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion proposal ratification appointment independent register public accounting firm begin caption preapproval policy service independent register public accounting firm fee service provide independent register public accounting firm company proxy statement annual meeting shareholder hold table content item